0001411685 2019-04-01 2019-12-31 0001411685 2019-03-31 0001411685 2019-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-03-31 0001411685 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001411685 us-gaap:SeriesBPreferredStockMember 2019-03-31 0001411685 us-gaap:SeriesCPreferredStockMember 2019-12-31 0001411685 us-gaap:SeriesCPreferredStockMember 2019-03-31 0001411685 2018-03-31 0001411685 2018-12-31 0001411685 us-gaap:CommonStockMember 2019-03-31 0001411685 us-gaap:CommonStockMember 2019-12-31 0001411685 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001411685 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001411685 us-gaap:TreasuryStockMember 2019-03-31 0001411685 us-gaap:TreasuryStockMember 2019-12-31 0001411685 us-gaap:RetainedEarningsMember 2019-03-31 0001411685 us-gaap:RetainedEarningsMember 2019-12-31 0001411685 VTGN:NotesPayable1Member 2019-12-31 0001411685 VTGN:NotesPayable1Member 2019-03-31 0001411685 2018-04-01 2018-12-31 0001411685 VTGN:CRLMember 2019-04-01 2019-12-31 0001411685 VTGN:CRLMember 2018-04-01 2018-12-31 0001411685 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-12-31 0001411685 us-gaap:ResearchAndDevelopmentExpenseMember 2018-04-01 2018-12-31 0001411685 us-gaap:GeneralAndAdministrativeExpenseMember 2019-04-01 2019-12-31 0001411685 us-gaap:GeneralAndAdministrativeExpenseMember 2018-04-01 2018-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-04-01 2019-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2018-04-01 2018-12-31 0001411685 us-gaap:SeriesBPreferredStockMember 2018-04-01 2018-12-31 0001411685 us-gaap:SeriesBPreferredStockMember 2019-04-01 2019-12-31 0001411685 VTGN:IncentivePlanMember 2019-04-01 2019-12-31 0001411685 VTGN:IncentivePlanMember 2018-04-01 2018-12-31 0001411685 us-gaap:WarrantMember 2019-04-01 2019-12-31 0001411685 us-gaap:WarrantMember 2018-04-01 2018-12-31 0001411685 us-gaap:SeriesCPreferredStockMember 2019-04-01 2019-12-31 0001411685 us-gaap:SeriesCPreferredStockMember 2018-04-01 2018-12-31 0001411685 VTGN:Warrant1Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant2Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant3Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant4Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant5Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant6Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant7Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant8Member 2019-04-01 2019-12-31 0001411685 VTGN:Warrant1Member 2019-12-31 0001411685 VTGN:Warrant2Member 2019-12-31 0001411685 VTGN:Warrant3Member 2019-12-31 0001411685 VTGN:Warrant4Member 2019-12-31 0001411685 VTGN:Warrant5Member 2019-12-31 0001411685 VTGN:Warrant6Member 2019-12-31 0001411685 VTGN:Warrant7Member 2019-12-31 0001411685 VTGN:Warrant8Member 2019-12-31 0001411685 us-gaap:CommonStockMember 2018-03-31 0001411685 us-gaap:CommonStockMember 2018-12-31 0001411685 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001411685 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001411685 us-gaap:TreasuryStockMember 2018-03-31 0001411685 us-gaap:TreasuryStockMember 2018-12-31 0001411685 us-gaap:RetainedEarningsMember 2018-03-31 0001411685 us-gaap:RetainedEarningsMember 2018-12-31 0001411685 us-gaap:EquipmentMember 2019-12-31 0001411685 VTGN:TenantImprovementsMember 2019-12-31 0001411685 us-gaap:ComputerEquipmentMember 2019-12-31 0001411685 us-gaap:OfficeEquipmentMember 2019-12-31 0001411685 us-gaap:EquipmentMember 2019-03-31 0001411685 VTGN:TenantImprovementsMember 2019-03-31 0001411685 us-gaap:ComputerEquipmentMember 2019-03-31 0001411685 us-gaap:OfficeEquipmentMember 2019-03-31 0001411685 VTGN:Plan2016Member 2019-12-31 0001411685 VTGN:Plan2016Member 2019-04-01 2019-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-03-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2018-03-31 0001411685 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001411685 us-gaap:SeriesBPreferredStockMember 2019-03-31 0001411685 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001411685 us-gaap:SeriesBPreferredStockMember 2018-03-31 0001411685 us-gaap:SeriesBPreferredStockMember 2018-12-31 0001411685 us-gaap:SeriesCPreferredStockMember 2019-03-31 0001411685 us-gaap:SeriesCPreferredStockMember 2019-12-31 0001411685 us-gaap:SeriesCPreferredStockMember 2018-03-31 0001411685 us-gaap:SeriesCPreferredStockMember 2018-12-31 0001411685 2019-10-01 2019-12-31 0001411685 2018-10-01 2018-12-31 0001411685 us-gaap:ResearchAndDevelopmentExpenseMember 2019-10-01 2019-12-31 0001411685 us-gaap:ResearchAndDevelopmentExpenseMember 2018-10-01 2018-12-31 0001411685 us-gaap:GeneralAndAdministrativeExpenseMember 2019-10-01 2019-12-31 0001411685 us-gaap:GeneralAndAdministrativeExpenseMember 2018-10-01 2018-12-31 0001411685 VTGN:CRLMember 2019-10-01 2019-12-31 0001411685 VTGN:CRLMember 2018-10-01 2018-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-04-01 2019-06-30 0001411685 us-gaap:SeriesAPreferredStockMember 2018-04-01 2018-06-30 0001411685 us-gaap:SeriesAPreferredStockMember 2019-10-01 2019-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2018-10-01 2018-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-06-30 0001411685 us-gaap:SeriesAPreferredStockMember 2018-06-30 0001411685 us-gaap:SeriesBPreferredStockMember 2019-04-01 2019-06-30 0001411685 us-gaap:SeriesBPreferredStockMember 2018-04-01 2018-06-30 0001411685 us-gaap:SeriesBPreferredStockMember 2019-10-01 2019-12-31 0001411685 us-gaap:SeriesBPreferredStockMember 2018-10-01 2018-12-31 0001411685 us-gaap:SeriesBPreferredStockMember 2019-06-30 0001411685 us-gaap:SeriesBPreferredStockMember 2018-06-30 0001411685 us-gaap:SeriesCPreferredStockMember 2019-04-01 2019-06-30 0001411685 us-gaap:SeriesCPreferredStockMember 2018-04-01 2018-06-30 0001411685 us-gaap:SeriesCPreferredStockMember 2019-10-01 2019-12-31 0001411685 us-gaap:SeriesCPreferredStockMember 2018-10-01 2018-12-31 0001411685 us-gaap:SeriesCPreferredStockMember 2019-06-30 0001411685 us-gaap:SeriesCPreferredStockMember 2018-06-30 0001411685 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001411685 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001411685 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001411685 us-gaap:CommonStockMember 2018-10-01 2018-12-31 0001411685 us-gaap:CommonStockMember 2019-06-30 0001411685 us-gaap:CommonStockMember 2018-06-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001411685 us-gaap:AdditionalPaidInCapitalMember 2018-10-01 2018-12-31 0001411685 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001411685 us-gaap:TreasuryStockMember 2019-04-01 2019-06-30 0001411685 us-gaap:TreasuryStockMember 2018-04-01 2018-06-30 0001411685 us-gaap:TreasuryStockMember 2019-10-01 2019-12-31 0001411685 us-gaap:TreasuryStockMember 2018-10-01 2018-12-31 0001411685 us-gaap:TreasuryStockMember 2019-06-30 0001411685 us-gaap:TreasuryStockMember 2018-06-30 0001411685 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001411685 us-gaap:RetainedEarningsMember 2018-04-01 2018-06-30 0001411685 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001411685 us-gaap:RetainedEarningsMember 2018-10-01 2018-12-31 0001411685 us-gaap:RetainedEarningsMember 2019-06-30 0001411685 us-gaap:RetainedEarningsMember 2018-06-30 0001411685 2019-04-01 2019-06-30 0001411685 2018-04-01 2018-06-30 0001411685 2019-06-30 0001411685 2018-06-30 0001411685 VTGN:Plan2019Member 2019-12-31 0001411685 VTGN:Plan2019Member 2019-04-01 2019-12-31 0001411685 us-gaap:SeriesAPreferredStockMember 2019-07-01 2019-09-30 0001411685 us-gaap:SeriesAPreferredStockMember 2018-07-01 2018-09-30 0001411685 us-gaap:SeriesAPreferredStockMember 2019-09-30 0001411685 us-gaap:SeriesAPreferredStockMember 2018-09-30 0001411685 us-gaap:SeriesBPreferredStockMember 2019-07-01 2019-09-30 0001411685 us-gaap:SeriesBPreferredStockMember 2018-07-01 2018-09-30 0001411685 us-gaap:SeriesBPreferredStockMember 2019-09-30 0001411685 us-gaap:SeriesBPreferredStockMember 2018-09-30 0001411685 us-gaap:SeriesCPreferredStockMember 2019-07-01 2019-09-30 0001411685 us-gaap:SeriesCPreferredStockMember 2018-07-01 2018-09-30 0001411685 us-gaap:SeriesCPreferredStockMember 2019-09-30 0001411685 us-gaap:SeriesCPreferredStockMember 2018-09-30 0001411685 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0001411685 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001411685 us-gaap:CommonStockMember 2019-09-30 0001411685 us-gaap:CommonStockMember 2018-09-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001411685 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001411685 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0001411685 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0001411685 us-gaap:TreasuryStockMember 2019-09-30 0001411685 us-gaap:TreasuryStockMember 2018-09-30 0001411685 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001411685 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0001411685 us-gaap:RetainedEarningsMember 2019-09-30 0001411685 us-gaap:RetainedEarningsMember 2018-09-30 0001411685 2019-07-01 2019-09-30 0001411685 2018-07-01 2018-09-30 0001411685 2019-09-30 0001411685 2018-09-30 0001411685 2020-02-11 0001411685 VTGN:Plan2019Member VTGN:Grant1Member 2019-12-31 0001411685 VTGN:Plan2019Member VTGN:Grant1Member 2019-04-01 2019-12-31 0001411685 VTGN:Plan2019Member VTGN:Grant2Member 2019-12-31 0001411685 VTGN:Plan2019Member VTGN:Grant2Member 2019-04-01 2019-12-31 0001411685 VTGN:Plan2019Member VTGN:Grant3Member 2019-12-31 0001411685 VTGN:Plan2019Member VTGN:Grant3Member 2019-04-01 2019-12-31 0001411685 VTGN:Plan2019Member VTGN:Grant4Member 2019-12-31 0001411685 VTGN:Plan2019Member VTGN:Grant4Member 2019-04-01 2019-12-31 0001411685 VTGN:Fall2019PrivatePlacementMember 2019-12-31 0001411685 VTGN:Fall2019PrivatePlacementMember 2019-04-01 2019-12-31 0001411685 VTGN:Winter2019WarrantModificationMember VTGN:PreModificationMember 2019-12-31 0001411685 VTGN:Winter2019WarrantModificationMember VTGN:PreModificationMember 2019-04-01 2019-12-31 0001411685 VTGN:Winter2019WarrantModificationMember VTGN:PostModificationMember 2019-12-31 0001411685 VTGN:Winter2019WarrantModificationMember VTGN:PostModificationMember 2019-04-01 2019-12-31 0001411685 VTGN:December2019WarrantModificationMember VTGN:PreModificationMember 2019-12-31 0001411685 VTGN:December2019WarrantModificationMember VTGN:PreModificationMember 2019-04-01 2019-12-31 0001411685 VTGN:December2019WarrantModificationMember VTGN:PostModificationMember 2019-12-31 0001411685 VTGN:December2019WarrantModificationMember VTGN:PostModificationMember 2019-04-01 2019-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure VistaGen Therapeutics, Inc. 0001411685 10-Q 2019-12-31 false --03-31 Yes Non-accelerated Filer Q3 2020 .001 0.001 10000000 10000000 500000 500000 4000000 4000000 3000000 3000000 .001 .001 100000000 175000000 false true false 14011700 5330800 47800 47800 0 3665600 312700 235100 13651200 1382300 250900 319000 300000 0 13100300 1063300 10378300 6285300 2800900 2936800 3000 3200 0 301400 57300 70500 1685600 951300 1055000 1610400 6936500 11425400 4135600 8488600 6300 3900 0 3798400 381100 0 3748200 4686300 500 500 1200 1200 2300 2300 14011700 5330800 -181133400 -198640700 3968100 3968100 192129900 196466000 42800 44200 500000 500000 1160240 1160240 2318012 2318012 500000 500000 1160240 1160240 2318012 2318012 42758630 44228630 42758630 44228630 135665 135665 250900 319000 20500 48200 22300 30500 96300 119300 105900 0 1246100 1246100 892500 214400 54600 84600 892500 214400 54600 84600 933400 1011000 14700 14700 6500 8700 8200 6000 6700 7900 172100 66800 439200 0 1067600 876600 57300 70500 70500 57300 0 0 0 0 57300 70500 70500 57300 42758630 44228630 23068280 31204380 1220000 500000 500000 500000 500000 1160240 1160240 1160240 1160240 2318012 2318012 2318012 2318012 500000 500000 1160240 1160240 2318012 2318012 42758630 23213280 170000 500000 500000 1160240 1160240 2318012 2318012 42758630 28676715 1575000 65000 250000 100000 325000 6611759 6611759 80431 80431 7075200 -6094600 6916600 1692800 42800 44200 192129900 196466000 -3968100 -3968100 -181133400 -198640700 23100 31200 16740400 181035800 -3968100 -3968100 -156543800 -175410100 500 500 500 500 1200 1200 1200 1200 2300 2300 2300 2300 500 500 1200 1200 2300 2300 42800 23200 192890400 167920900 -3968100 -3968100 -187343300 -160758300 1625800 3221700 500 500 1200 1200 2300 2300 42800 28700 193352000 176117900 -3968100 -3968100 -193061200 -168193300 -3630400 3989200 40000 650000 1202939 3783000 650000 1852600 600 1200 50000 649400 1851400 50000 3800 4725000 4728800 5000 820000 398800 410000 605700 410000 598200 800 400 7500 409200 597800 7500 -321800 -290900 -302500 -273500 -321800 -290900 -302500 -273500 -313800 -283600 -313800 -283600 1632200 734700 1063000 612600 1632200 734700 1063000 612600 775400 1172400 775400 1172400 100000 50000 100 122900 123000 100 334800 334900 -5961500 -7216800 -6209900 -4214500 -5961500 -7216800 -6209900 -4214500 -5717900 -7435000 -5717900 -7435000 925926 1630435 2000000 900 1999100 1600 2248400 2250000 47963042 17538100 18834400 5962800 7192300 6004500 5494100 2948300 1856800 11533600 13340300 108400 11700 3014500 5335500 5600 0 -17538100 -18834400 -5962800 -7192300 0 -22700 0 -22700 -33400 6800 -1500 1800 -18445400 -19714300 -6283300 -7507700 938100 848000 321800 290900 -17507300 -18866300 -5961500 -7216800 2600 2400 200 0 -17504700 -18863900 -5961300 -7216800 -.43 -0.75 -.15 -0.24 42802256 26418440 43158889 30696312 0 40000 938100 848000 230200 160500 13800 79800 0 4250000 92100 277600 826900 25800 3088700 2519700 1060600 955600 2028100 1564100 1632200 734700 502500 274900 1129700 459800 77600 64800 -13177800 -10970300 0 109200 -178900 511800 -196300 0 -249400 0 -56200 -34600 -300000 0 0 -169800 0 169800 -12037000 -4093000 1140800 7047100 217000 165300 2200 2000 300000 0 650000 6608700 826900 25800 826900 25800 300000 300000 <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">VistaGen Therapeutics. Inc., a Nevada corporation (which may be referred to as <i>VistaGen</i>, the <i>Company</i>, <i>we</i>, <i>our</i>, or <i>us</i>), is a clinical-stage biopharmaceutical company committed to developing new generation medications for central nervous system (<i>CNS</i>) diseases and disorders with high unmet need. Our pipeline includes three clinical-stage CNS drug candidates, each with a differentiated mechanism of action, an exceptional safety profile in all clinical studies to date, and therapeutic potential in multiple CNS markets. We aim to become a fully-integrated biopharmaceutical company that develops and commercializes innovative CNS therapies for large and growing mental health and neurology markets where current treatments are inadequate to meet the needs of millions of patients and caregivers worldwide.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>PH94B Neuroactive Nasal Spray for Anxiety-related Disorders</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PH94B neuroactive nasal spray is an odorless, first-in-class, fast-acting synthetic neurosteroid with therapeutic potential in a wide range of neuropsychiatric indications involving anxiety or phobia. Conveniently self-administered in microgram doses without systemic exposure, we are initially developing PH94B as a potential fast-acting, non-sedating, non-addictive new generation treatment of social anxiety disorder (<i>SAD</i>). SAD affects over 20 million Americans and, according to the National Institutes of Health (<i>NIH</i>), is the third most common psychiatric condition after depression and substance abuse. A person with SAD feels symptoms of anxiety or fear in certain social situations, such as meeting new people, dating, being on a job interview, answering a question in class, or having to talk to a cashier in a store. Doing everyday things in front of people - such as eating or drinking in front of others or using a public restroom - also causes anxiety or fear. A person with SAD is afraid that he or she will be humiliated, judged, and rejected.&#160; The fear that people with SAD have in social situations is so strong that they feel it is beyond their ability to control. As a result, it gets in the way of going to work, attending school, or doing everyday things in situations with potential for interpersonal interaction. People with SAD may worry about these and other things for weeks before they happen. Sometimes, they end up staying away from places or events where they think they might have to do something that will embarrass them.&#160; Some people with SAD do not have anxiety in social situations, but instead have performance anxiety. They feel physical symptoms of anxiety in performance situations, such as giving a lecture, a speech or a presentation at school or work, as well as playing a sports game, or dancing or playing a musical instrument on stage.&#160; Without treatment, SAD can last for many years or a lifetime and prevent a person from reaching his or her full potential.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Only three drugs, all oral antidepressants (<i>ADs</i>), are approved by the U.S Food and Drug Administration (<i>FDA</i>) specifically for treatment of SAD. These FDA-approved chronic ADs have slow onset of effect (often many weeks to months) and significant side effects that may make them inadequate or inappropriate treatment alternatives for many individuals affected by SAD episodically. VistaGen&#8217;s PH94B is fundamentally differentiated from all current anxiolytics, including all ADs approved by the FDA for treatment of SAD. Intranasal self-administration of only approximately 3.2 micrograms of PH94B binds to nasal chemosensory receptors that, in turn, activate key neural circuits in the brain that lead to rapid suppression of fear and anxiety. In Phase 2 and pilot Phase 3 clinical studies to date, PH94B has not shown psychological side effects (such as dissociation or hallucinations), systemic exposure, sedation or other side effects and safety concerns that may be caused by the current ADs approved by the FDA for treatment of SAD, as well as with the benzodiazepines and beta blockers, which are not approved by the FDA to treat SAD but may be prescribed by psychiatrists and physicians for treatment of SAD on an off-label basis.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In a peer-reviewed, published double-blind, placebo-controlled Phase 2 clinical trial, PH94B neuroactive nasal spray was significantly more effective than placebo in reducing both public-speaking (performance) anxiety (p=0.002) and social interaction anxiety (p=0.009) in laboratory challenges of individuals with SAD within 10 to 15 minutes of self-administration of a non-systemic 1.6 microgram dose of PH94B.&#160; Based on its novel mechanism of pharmacological action, rapid-onset of therapeutic effects and exceptional safety and tolerability profile in Phase 2 and pilot Phase 3 clinical trials to date, we are preparing to begin Phase 3 development of PH94B. Our goal is to develop and commercialize PH94B as the first FDA-approved, fast-acting, on-demand, at-home treatment for SAD. Additional potential anxiety-related neuropsychiatric indications for PH94B include general anxiety disorder, peripartum anxiety (pre- and post-partum anxiety), pre/post-operative anxiety, panic disorder, post-traumatic stress disorder and specific social phobias.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>PH10 Neuroactive Nasal Spray for Depression and Suicidal Ideation</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PH10 neuroactive nasal spray is an odorless, first-in-class, fast-acting synthetic neurosteroid with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. Conveniently self-administered in microgram doses without systemic exposure, we are initially developing PH94B as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (<i>MDD</i>).</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Depression is a serious medical illness and a global public health concern that can occur at any time over a person's life. While most people will experience depressed mood at some point during their lifetime, MDD is different. MDD is the chronic, pervasive feeling of utter unhappiness and suffering, which impairs daily functioning. Symptoms of MDD include diminished pleasure or loss of interest in activities, changes in appetite that result in weight changes, insomnia or oversleeping, psychomotor agitation, loss of energy or increased fatigue, feelings of worthlessness or inappropriate guilt, difficulty thinking, concentrating or making decisions, and thoughts of death or suicide and attempts at suicide. Current FDA-approved medications available in the multi-billion-dollar global AD market often fall far short of satisfying the unmet medical needs of millions suffering from the debilitating effects of depression.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">While current FDA-approved ADs are widely used, about two-thirds of patients with MDD do not respond to their initial AD treatment. Inadequate response to current ADs is among the key reasons MDD is one of the leading public health concerns in the United States, creating a significant unmet medical need for new agents with fundamentally different mechanisms of action and side effect and safety profiles.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">PH10 is a new generation antidepressant with a mechanism of action that is fundamentally different from all current ADs. After self-administration, a non-systemic microgram-level dose of PH10 binds to nasal chemosensory receptors that, in turn, activate key neural circuits in the brain that can lead to rapid-onset antidepressant effects, but without the psychological side effects (such as dissociation and hallucinations), systemic exposure or safety concerns that maybe be caused by ketamine-based therapy (<i>KBT</i>), including intravenous ketamine or esketamine nasal spray. In an exploratory 30-patient Phase 2a clinical trial, PH10, self-administered at a dose of 6.4 micrograms, was well-tolerated and demonstrated significant (p=0.022) rapid-onset antidepressant effects, which were sustained over an 8-week period, as measured by the Hamilton Depression Rating Scale (HAM-D), without side effects or safety concerns that may be caused by KBT. Based on positive results from this exploratory Phase 2a study, we are preparing for Phase 2b clinical development of PH10 in MDD. With its exceptional safety profile during clinical development to date, we believe PH10, as a convenient at-home therapy, has potential for multiple applications in global depression markets, including as a stand-alone front-line therapy for MDD, as an add-on therapy to augment current FDA-approved ADs for patients with MDD who have an inadequate response to standard ADs, and to prevent relapse following successful treatment with KBT.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>AV-101, an Oral NMDAR Antagonist</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">AV-101 (4-Cl-KYN) belongs to a new generation of investigational medicines in neuropsychiatry and neurology known as NMDAR (N-methyl-D-aspartate receptor) modulators. The NMDAR is a pivotal ion channel in the brain that is involved with transmitting signals between neurons, and abnormal NMDAR function is associated with numerous CNS diseases and disorders. AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective full antagonist of the NMDAR by blocking the glycine site. To date AV-101 has exhibited no dissociative or hallucinogenic psychological side effects or safety concerns similar to those that may be caused by amantadine and ketamine therapy. With this lack of side effects and exceptional safety profile, AV-101 has potential to be a new oral, at-home, non-sedating treatment for multiple large-market NMDAR-focused CNS indications where current treatments are inadequate to meet high unmet patient needs. The FDA has granted Fast Track designation for development of AV-101 as both a potential adjunctive treatment for MDD and as a non-opioid treatment for neuropathic pain.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recently completed a double-blind, placebo-controlled, multi-center Phase 2 clinical trial of AV-101 as a potential adjunctive treatment, together with a standard FDA-approved oral AD (either a selective serotonin reuptake inhibitor (<i>SSRI</i>) or a serotonin norepinephrine reuptake inhibitor (<i>SNRI</i>)), in MDD patients who had an inadequate response to a stable dose of a standard AD (the <i>Elevate Study</i>). Topline results of the Elevate Study (n=199) indicated that the AV-101 treatment arm (1440 mg) did not differentiate from placebo on the primary endpoint (change in the Montgomery-&#197;sberg Depression Rating Scale (MADRS-10) total score compared to baseline), potentially due to sub-therapeutic levels of 7-Cl-KYNA in the brain. As in prior clinical studies, AV-101 was well tolerated, with no psychotomimetic side effects or drug-related serious adverse events.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Results from recent successful AV-101 preclinical studies suggest that there is a substantially increased brain concentration of AV-101 and its active metabolite, 7-chlorokynurenic acid (7CL-KYNA), when given together with probenecid. These surprising effects were first revealed in those studies, although they are consistent with well-documented clinical studies of probenecid increasing the therapeutic levels of some unrelated classes of approved drugs. Probenecid otherwise is a safe and well-known organic anion transport inhibitor used, for example, to increase the therapeutic benefit of antibiotics. When probenecid was given adjunctively with AV-101 in an animal model, markedly increased brain concentrations of AV-101 (approximately 7-fold) and of 7-Cl-KYNA (approximately 35-fold) were discovered. The substantial increase in brain concentration of 7-Cl-KYNA in this animal model might have been due, in large part, to probenecid&#8217;s ability to block the efflux of 7-Cl-KYNA from the brain. This efflux-blocking effect, with a resulting increase in brain levels and duration of AV-101&#8217;s active metabolite, potentially could have important therapeutic implications for human patients with MDD and potentially other NMDAR-focused CNS diseases and disorders. Some of the findings from these AV-101 preclinical studies with adjunctive probenecid were presented at the British Pharmacological Society&#8217;s Pharmacology 2019 annual conference in Edinburgh, UK in December 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition, a Phase 1b target engagement study completed after the Elevate Study by the Baylor College of Medicine (<i>Baylor</i>) with financial support from the U.S. Department of Veterans Affairs (<i>VA</i>), involved 10 healthy volunteer U.S. military Veterans who received single doses of AV-101 (720 mg or 1440 mg) or placebo, in a double-blind, randomized, cross-over controlled trial. The primary goal of the study was to identify and define a dose-response relationship between AV-101 and multiple electrophysiological (<i>EEG</i>) biomarkers related to NMDAR function, as well as blood biomarkers associated with suicidality (the <i>Baylor Study</i>). The findings from the Baylor Study suggest that, in healthy Veterans, the higher dose of AV-101 (1440 mg) was associated with dose-related increase in the 40 Hz Auditory Steady State Response (<i>ASSR</i>), a robust measure of the integrity of inhibitory interneuron synchronization that is associated with NMDAR inhibition. Findings from the successful Baylor Study were presented at the 58th Annual Meeting of the American College of Neuropsychopharmacology (<i>ACNP</i>) in Orlando, Florida in December 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The successful Baylor Study and preclinical studies involving adjunctive probenecid suggest that it may be possible to increase therapeutic concentrations and duration of 7-Cl-KYNA in the brain, and thus increase NMDAR antagonism in MDD patients with an inadequate response to standard ADs when AV-101 and probenecid are combined. During 2020, we plan to conduct additional AV-101 preclinical studies with adjunctive probenecid to evaluate its potential applicability to other NMDAR-focused CNS indications for which we have existing data with AV-101 as a monotherapy (epilepsy, levodopa-induced dyskinesia, neuropathic pain and suicidal ideation), to determine the most appropriate path forward for potential clinical development of AV-101 in MDD and possibly other indications.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>VistaStem Therapeutics &#8211; Stem Cell Technology for Drug Rescue and Regenerative Medicine</i></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In addition to our current CNS drug candidates, we have stem cell technology-based, pipeline-enabling programs through our wholly-owned subsidiary, VistaStem Therapeutics (<i>VistaStem</i>). VistaStem is focused on applying pluripotent stem cell (<i>hPSC</i>) technology to discover and develop, by utilizing&#160;<i>CardioSafe 3D</i>, our customized cardiac bioassay system, small molecule New Chemical Entities (<i>NCEs</i>) for our CNS pipeline or for out-licensing.&#160;VistaStem&#8217;s stem cell technology involving hPSC-derived blood, cartilage, heart and liver cells has multiple potential applications. To advance potential regenerative medicine (<i>RM</i>) applications of VistaStem&#8217;s cardiac stem cell technology, we licensed to BlueRock Therapeutics LP, a next generation cell therapy and RM company which was acquired by Bayer AG in 2019, rights to certain proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease (the&#160;<i>BlueRock/Bayer Agreement</i>).&#160;In a manner similar to the BlueRock/Bayer Agreement, we may pursue additional collaborations or licensing transactions involving VistaStem&#8217;s blood, cartilage, and/or liver cells derived from hPSCs for cell-based therapy, cell repair therapy, RM and/or tissue engineering.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Subsidiaries</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As noted above, VistaStem, a California corporation, is our wholly-owned subsidiary. Our Condensed Consolidated Financial Statements in this Quarterly Report on Form 10-Q (<i>Report</i>) also include the accounts of VistaStem and VistaStem&#8217;s two wholly-owned inactive subsidiaries, Artemis Neuroscience, Inc., a Maryland corporation, and VistaStem Canada, Inc., a corporation organized under the laws of Ontario, Canada.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the United States (<i>U.S. GAAP</i>) for interim financial information and with the instructions to Form 10-Q and Rule&#160;8-03 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required for complete consolidated financial statements. In the opinion of management, the accompanying unaudited Condensed Consolidated Financial Statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim financial information. The accompanying Condensed Consolidated Balance Sheet at March 31, 2019 has been derived from our audited consolidated financial statements at that date but does not include all disclosures required by U.S. GAAP.&#160; The operating results for the three and nine months ended December 31, 2019 are not necessarily indicative of the operating results to be expected for our fiscal year ending March 31, 2020, or for any other future interim or other period.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited Condensed Consolidated Financial Statements and notes to the Condensed Consolidated Financial Statements contained in this Report should be read in conjunction with our audited Consolidated Financial Statements for our fiscal year ended March 31, 2019 contained in our Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (<i>SEC</i>) on June 25, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared assuming we will continue as a going concern. As a clinical-stage biopharmaceutical company having not yet developed commercial products or achieved sustainable revenues, we have experienced recurring losses and negative cash flows from operations resulting in a deficit of approximately $198.6 million accumulated from inception (May 1998) through December 31, 2019. We expect losses and negative cash flows from operations to continue for the foreseeable future as we engage in further development of PH94B, PH10 and AV-101, execute our drug rescue programs and pursue potential drug development and regenerative medicine opportunities.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Since our inception in May 1998 through December 31, 2019, we have financed our operations and technology acquisitions primarily through the issuance and sale of our equity and debt securities for cash proceeds of approximately $80.4 million, as well as from an aggregate of approximately $17.7 million of government research grant awards (excluding the fair market value of government sponsored and funded clinical trials), strategic collaboration payments, intellectual property licensing and other revenues. Additionally, we have issued equity securities with an approximate value at issuance of $38.1 million in noncash acquisitions of product licenses and in settlements of certain liabilities, including liabilities for professional services rendered to us or as compensation for such services.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2019, we had cash and cash equivalents of approximately $1.1 million. As disclosed in Note 11, <i>Subsequent Events</i>, since December 31, 2019, we have received net cash proceeds of approximately $2.68 million from a registered direct public offering of our common stock and a concurrent private placement of warrants to purchase unregistered shares of our common stock (the <i>January 2020 Offering</i>). Nevertheless, in the absence of additional financing from the sale of our securities, government research grant awards, strategic collaboration payments, intellectual property licensing or other sources, we believe that our cash position at December 31, 2019, together with the proceeds from the January 2020 Offering, will not be sufficient to fund our planned operations for the twelve months following the issuance of these financial statements and raises substantial doubt that we can continue as a going concern. During the next twelve months, subject to securing appropriate and adequate financing, we plan to prepare for and launch a Phase 3 clinical trial of PH94B for SAD, prepare for a Phase 2b clinical study and certain nonclinical studies involving PH10, PH94B and AV-101 and prepare for and potentially launch a Phase 2b clinical trial of PH10 for MDD. When necessary and advantageous, we plan to raise additional capital, through the sale of our equity securities in one or more (i) private placements to accredited investors, (i) public offerings and/or (ii) in strategic licensing and development collaborations involving one or more of our drug candidates in markets outside the United States. Subject to certain restrictions, our Registration Statement on Form S-3 (Registration No. 333-234025) (the <i>S-3 Registration Statement</i>), which became effective on October 7, 2019, is available for future sales of our equity securities in one or more public offerings from time to time. While we may make additional sales of our equity securities under the S-3 Registration Statement, we do not have an obligation to do so.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As we have been in the past, we expect that, when and as necessary, we will be successful in raising additional capital from the sale of our equity securities either in one or more public offerings or in one or more private placement transactions with individual accredited investors and institutions. In addition to the potential sale of our equity securities, we may also seek to enter research, development and/or commercialization collaborations that could generate revenue or provide funding, including non-dilutive funding, for development of one or more of our CNS product candidates. We may also seek additional government grant awards or agreements similar to our relationships with Baylor and the VA in connection with the Baylor Study. Such strategic collaborations may provide non-dilutive resources to advance our strategic initiatives while reducing a portion of our future cash outlays and working capital requirements. We may also pursue intellectual property arrangements similar to the BlueRock/Bayer Agreement with other parties. Although we may seek additional collaborations that could generate revenue and/or provide non-dilutive funding for development of our product candidates, as well as new government grant awards and/or agreements, no assurance can be provided that any such collaborations, awards or agreements will occur in the future. &#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our future working capital requirements will depend on many factors, including, without limitation, the scope and nature of opportunities related to our success and the success of certain other companies in clinical trials, including our development and commercialization of our current product candidates and various applications of our stem cell technology platform, the availability of, and our ability to obtain, government grant awards and agreements, and our ability to enter into collaborations on terms acceptable to us. To further advance the clinical development of PH94B, PH10, and AV-101 and, to a lesser extent, our stem cell technology platform, as well as support our operating activities, we plan to continue to carefully manage our routine operating costs, including our employee headcount and related expenses, as well as costs relating to regulatory consulting, contract research and development, investor relations and corporate development, legal, acquisition and protection of intellectual property, public company compliance and other professional services and operating costs.&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Notwithstanding the foregoing, there can be no assurance that future financings or government or other strategic collaborations will be available to us in sufficient amounts, in a timely manner, or on terms acceptable to us, if at all. If we are unable to obtain substantial additional financing on a timely basis when needed in 2020 and beyond, our business, financial condition, and results of operations may be harmed, the price of our stock may decline, we may be required to reduce, defer, or discontinue certain of our research and development activities and we may not be able to continue as a going concern.&#160;&#160;As noted above, these Condensed Consolidated Financial Statements do not include any adjustments that might result from the negative outcome of this uncertainty.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Use of Estimates</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&#160;&#160;Significant estimates include those relating to share-based compensation, right-of-use assets and lease liabilities and assumptions that have been used historically to value warrants and warrant modifications. With the exception of the BlueRock/Bayer Agreement pursuant to which we recorded sublicense revenue in the third quarter of our fiscal year ended March 31, 2017, we do not currently have, nor have we had during the periods covered by this Report, any arrangements requiring the recognition of revenue.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Research and Development Expenses</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses are composed of both internal and external costs.&#160;&#160;Internal costs include salaries and employment-related expenses, including stock-based compensation expense, of scientific personnel and direct project costs.&#160;&#160;External research and development expenses consist primarily of costs associated with clinical and non-clinical development of PH94B, PH10, AV-101, and stem cell research and development costs, and costs related to the application and prosecution of patents related to those product candidates and, to a lesser extent, our stem cell technology platform. All such costs are charged to expense as incurred. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by contract research organizations (<i>CRO</i>s) and clinical trial sites. Progress payments are generally made to CROs, clinical sites, investigators and other professional service providers. We analyze the progress of the clinical trial, including levels of subject enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the clinical trial accrual in any reporting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to research and development expense in the period in which the facts that give rise to the revision become known. Costs incurred in obtaining product or technology licenses are charged immediately to research and development expense if the product or technology licensed has not achieved regulatory approval or reached technical feasibility and has no alternative future uses. In September and October 2018, we acquired exclusive worldwide licenses to develop and commercialize PH94B and PH10, respectively, by issuing an aggregate of 2,556,361 unregistered shares of our common stock having an issuance-date fair market value of $4,250,000. Since, at the date of each acquisition, neither product candidate had achieved regulatory approval and each requires significant additional development and expense, we expensed the costs related to acquiring the licenses and the option during our fiscal year ended March 31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Stock-Based Compensation</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize compensation cost for all stock-based awards to employees and non-employee consultants based on the grant date fair value of the award.&#160;&#160;We record non-cash, stock-based compensation expense over the period during which the employee or other grantee is required to perform services in exchange for the award, which generally represents the scheduled vesting period.&#160;&#160;We have not granted restricted stock awards to employees nor do we have any awards with market or performance conditions.&#160;Non-cash expense attributable to compensatory grants of stock to non-employees is determined by the quoted market price of the stock on the date of grant and is either recognized as fully-earned at the time of the grant or amortized ratably over the term of the related service agreement, depending on the terms of the specific agreement.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below summarizes stock-based compensation expense included in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended December 31, 2019 and 2018.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;Three Months Ended December 31,</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;Nine Months Ended December 31,</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2019</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2018</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2019</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2018</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 50%; font-size: 8pt">&#160;Research and development expense</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">502,500</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">274,900</td> <td style="width: 2%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">1,060,600</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">955,600</td> <td style="width: 2%; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;General and administrative expense</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">1,129,700</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">459,800</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">2,028,100</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">1,564,100</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;Total stock-based compensation expense</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">1,632,200</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">734,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">3,088,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">2,519,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, the Compensation Committee of our Board of Directors (the <i>Board</i>) approved the grant of options from our 2016 Amended and Restated Stock Incentive Plan (the <i>2016 Plan</i>) to purchase an aggregate of 1,220,000 shares of our common stock at a then above-market exercise price of $1.00 per share to the independent members of our Board, our officers and employees and certain consultants. The options vested 25% upon grant with the remaining shares vesting ratably over three years for independent directors, officers and employees, and over two years for consultants. We valued the options granted in May 2019 using the Black-Scholes Option Pricing Model and the following weighted average assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, the Compensation Committee of our Board of Directors (the <i>Board</i>) approved the grant of options from our 2016 Amended and Restated Stock Incentive Plan (the <i>2016 Plan</i>) to purchase an aggregate of 1,220,000 shares of our common stock at a then above-market exercise price of $1.00 per share to the independent members of our Board, our officers and employees and certain consultants. The options vested 25% upon grant with the remaining shares vesting ratably over three years for independent directors, officers and employees, and over two years for consultants. We valued the options granted in May 2019 using the Black-Scholes Option Pricing Model and the following weighted average assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Assumption:</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid">May 2019</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 87%; font-size: 8pt; text-align: justify">Market price per share at grant date</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.80</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.00</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2.12</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Expected term in years</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.53</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">85.90</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.0</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,220,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold">Fair Value per share</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td style="font-size: 8pt; font-weight: bold; text-align: left">$</td><td style="font-size: 8pt; font-weight: bold; text-align: right">0.54</td><td style="font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in May 2019, the Compensation Committee approved, subject to subsequent stockholder approval at our 2019 Annual Meeting of Stockholders (<i>Annual Meeting</i>) held in September 2019, the 2019 Omnibus Equity Incentive Plan (the <i>2019 Plan</i>) and designated 7.5 million shares of our authorized common stock to be reserved thereunder. Further, in May 2019, the Compensation Committee granted options pursuant to the 2019 Plan to one of our officers to purchase 170,000 shares of our common stock at a then above-market exercise price of $1.00 per share, which grant was contingent upon the approval of the 2019 Plan by our stockholders. Our stockholders approved the 2019 Plan at our Annual Meeting and ratified the contingent grant. The option vested 25% upon approval of the 2019 Plan and the remaining shares vest ratably over three years. We valued the option using the Black-Scholes Option Pricing Model and the following assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Assumption:</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid">September 2019</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 87%; font-size: 8pt; text-align: justify">Market price per share at grant date</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.84</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.00</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.45</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Expected term in years</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.58</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">86.04</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.0</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">170,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold">Fair Value per share</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td style="font-size: 8pt; font-weight: bold; text-align: left">$</td><td style="font-size: 8pt; font-weight: bold; text-align: right">0.56</td><td style="font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon approval of the 2019 Plan by our stockholders, no further option or other equity awards were permitted from our 2016 Plan and all remaining authorized shares of our common stock available for issuance under the 2016 Plan, 1,388,412 shares, became available for issuance under the 2019 Plan.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended December 31, 2019, we granted options from our 2019 Plan to the independent members of our Board, our officers and employees and certain consultants to purchase an aggregate of 1,990,000 shares of our common stock at exercise prices ranging from $0.50 to $1.41 per share. Options granted to Board members, officers, employees and most consultants were vested 25% at grant with the remaining options vesting ratably over the following 24 months. In the case of options granted to certain consultants, the options were vested 25% at grant but the remaining vesting period was less than 24 months to coincide with contractual terms. We valued the options using the Black-Scholes Option Pricing Model and the following assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td colspan="12" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>Options Granted on</b>&#160; &#160; &#160;&#160; &#160; &#160;&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>October 21, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;November 7, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;December 4, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;December 15, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 48%; font-size: 8pt">Exercise price</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1.41</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1.20</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.50</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.70</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Market price on date of grant</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.41</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.01</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.44</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.70</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.62</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.74</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.60</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.66</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Expected term (years)</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.39</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">87.52</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.02</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.28</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.44</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Expected dividend yield</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Fair value per share at grant date</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.99</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.67</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.30</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.49</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Number of shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,575,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">65,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">250,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">100,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2019, there were stock options outstanding under our 2016 Plan and 2019 Plan to purchase 9,928,088 shares of our common stock at a weighted average exercise price of $1.37 per share. At that date, there were also 6,805,162 shares of our common stock available for future issuance under the 2019 Plan. See Note 11, <i>Subsequent Events</i>, for disclosure of additional option grants made in January 2020.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Leases, Right-of-Use Assets and Lease Liabilities</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 1, 2019, we adopted Financial Accounting Standards Board (<i>FASB</i>) Accounting Standards Update (<i>ASU</i>) No.&#160;2016-02,&#160;<i>Leases</i>, which replaced the existing guidance in Accounting Standards Codification (<i>ASC</i>) 840, &#8220;Leases&#8221;, and its subsequent amendments including ASU No. 2018-11,&#160;<i>Leases (Topic 842):</i> Targeted&#160;Improvements (<i>ASC 842</i>) using the modified transition method.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We determine whether an arrangement is an operating or financing lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. In determining the present value of the lease payments, we use the interest rate implicit in the lease when it is readily determinable and we use our estimated incremental borrowing rate based upon information available at the commencement date when the implicit rate is not readily determinable.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The lease payments used to determine our operating lease assets include lease incentives and stated rent increases and may include escalation or other clauses linked to rates of inflation or other factors when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating leases are reflected in right of use asset &#8211; operating leases, other current liabilities and non-current operating lease liability in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our accounting for financing leases, previously referred to as &#8220;capital leases&#8221; under prior guidance, remained substantially unchanged with our adoption of ASC 842. Financing leases are included in property and equipment, net and as current and non-current financing lease liabilities in our condensed consolidated balance sheets. Refer to &#8220;Recent Accounting Pronouncements&#8221; below and Note 10, <i>Commitments and Contingencies,</i> for additional information regarding our adoption of ASC 842 and its impact on our condensed consolidated financial statements.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Comprehensive Loss</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no components of other comprehensive loss other than net loss, and accordingly our comprehensive loss is equivalent to our net loss for the periods presented.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>Loss per Common Share</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss attributable to common stockholders per share of common stock excludes the effect of dilution and is computed by dividing net loss increased by the accrual of dividends on outstanding shares of our Series B 10% Convertible Preferred Stock (<i>Series B Preferred</i>), by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue shares of common stock were exercised or converted into shares of common stock. In calculating diluted net loss attributable to common stockholders per share, we have generally not increased the denominator to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method because the result is antidilutive.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of our net loss for all periods presented, potentially dilutive securities were excluded from the computation of diluted net loss per share, as their effect would be antidilutive. Potentially dilutive securities excluded in determining diluted net loss attributable to common stockholders per common share are as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">As of December 31,</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">2019</td><td style="font-weight: bold; padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid; font-size: 8pt">2018</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center">&#160;</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 74%; text-align: left; font-size: 8pt">Series A Preferred stock issued and outstanding (1)</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td><td style="width: 10%; text-align: right; font-size: 8pt">750,000</td><td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td><td style="width: 10%; text-align: right; font-size: 8pt">750,000</td><td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: left; font-size: 8pt">Series B Preferred stock issued and outstanding (2)</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1,160,240</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1,160,240</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: left; font-size: 8pt">Series C Preferred stock issued and outstanding (3)</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">2,318,012</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">2,318,012</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: left; font-size: 8pt">Outstanding options under the Company's Amended and Restated 2016 (formerly 2008) Stock Incentive Plan and 2019 Omnibus Equity Incentive Plan</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">9,928,088</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">6,410,338</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: left; padding-bottom: 1pt; font-size: 8pt">Outstanding warrants to purchase common stock</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">23,050,204</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">21,499,955</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="padding-bottom: 2.5pt; font-size: 8pt">Total</td><td style="padding-bottom: 2.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">37,206,544</td><td style="padding-bottom: 2.5pt; text-align: left; font-size: 8pt">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">32,138,545</td><td style="padding-bottom: 2.5pt; text-align: left; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font-size: 8pt"> <td style="width: 70%; font-size: 8pt">____________</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 14%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 14%; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td colspan="5" style="font-size: 8pt">(1) Assumes exchange under the terms of the October 11, 2012 Note Exchange and Purchase Agreement, as amended.</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td colspan="5" style="font-size: 8pt">(2) Assumes exchange under the terms of the Certificate of Designation of the Relative Rights and Preferences of the Series B 10% Convertible Preferred Stock, effective May 5, 2015; excludes common shares issuable in payment of dividends on Series B Preferred upon conversion.</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td colspan="5" style="font-size: 8pt">(3) Assumes exchange under the terms of the Certificate of Designation of the Relative Rights and Preferences of the Series C Convertible Preferred Stock, effective January 25, 2016.</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Fair Value Measurements</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not use derivative instruments for hedging of market risks or for trading or speculative purposes. We carried no assets or liabilities that are measured on a recurring basis at fair value at December 31, 2019 or March&#160;31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>Recent Accounting Pronouncements</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as described below, there have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended December 31, 2019, as compared to the recent accounting pronouncements described in our Form 10-K for our fiscal year ended March 31, 2019, that are of significance or potential significance to us.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No.&#160;2016-02,&#160;<i>Leases</i>, which replaced the existing guidance in ASC 840, &#8220;Leases&#8221;, and in July 2018, the FASB issued ASU No. 2018-11,&#160;<i>Leases (Topic 842):</i> Targeted&#160;Improvements (together, <i>ASC 842</i>). The new leasing standards set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standards require lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to the prior guidance for operating leases. We adopted the standards on the required effective date of April 1, 2019 and did not restate lease expense or lease-related assets or liabilities reported in prior comparative periods.&#160;Presentation of our financing lease for office equipment in the consolidated balance sheet is generally consistent with capitalized lease presentation under the prior lease accounting guidance. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows is generally consistent with the prior lease accounting guidance. We elected the package of practical expedients permitted under the transition guidance and, accordingly, the adoption of ASC 842 did not change the prior classification of any of our leases.&#160;We elected not to record a right-of-use asset or a lease liability on the balance sheet for leases with a term of 12 months or less and will recognize the associated lease payments in the consolidated statements of operations over the lease term.&#160;On the April 1, 2019 adoption date, we recognized approximately $4.3 million as total lease liabilities and $3.9 million as total right-of-use assets in our Condensed Consolidated Balance Sheet and derecognized a deferred rent liability of approximately $0.4 million attributable to the operating lease of our primary office and laboratory facilities recorded in accordance with prior guidance.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Prepaid expenses and other current assets are composed of the following at December 31, 2019 and March 31, 2019:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; font-size: 8pt; text-align: left">&#160;Clinical and nonclinical materials and contract services</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">121,000</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">5,900</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Fair value of securities issued for professional services</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8212;&#160;&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">105,900</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">&#160;Insurance</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">119,300</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">96,300</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Public offering filing fees and expenses</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">30,500</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">22,300</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">&#160;Conferences, sponsorships and all other</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">48,200</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">20,500</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">319,000</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">250,900</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The fair value of securities issued for professional services reflects the unamortized portion of the fair value of securities we have issued to certain professional service providers as full or partial compensation for services. The fair value of the securities issued is amortized ratably over the term of the related service agreement.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="margin: 0pt"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Property and equipment is composed of the following at December 31, 2019 and March 31, 2019:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; font-size: 8pt; text-align: left">&#160;Laboratory equipment</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">892,500</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">892,500</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Tenant improvements</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">214,400</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">214,400</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Computers and network equipment</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">54,600</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">54,600</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">&#160;Office furniture and equipment</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">84,600</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">84,600</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,246,100</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,246,100</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">&#160;Accumulated depreciation and amortization</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(1,011,000</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(933,400</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 2.5pt">&#160;Property and equipment, net</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">235,100</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">312,700</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Included in amounts reported above for office furniture and equipment is the right-of-use asset related to a financing lease of certain office equipment. Amounts associated with assets subject to the financing lease at December 31, 2019 and March 31, 2019 are as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; font-size: 8pt; text-align: left">&#160;Office equipment subject to financing lease</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">14,700</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">14,700</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">&#160;Accumulated depreciation</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(8,700</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">(6,500</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 2.5pt">&#160;Net book value of office equipment subject to financing lease</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">6,000</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">8,200</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="margin: 0pt"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The following table summarizes our unsecured promissory notes at December 31, 2019 and March 31, 2019:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="3" style="vertical-align: bottom; padding-bottom: 1.5pt"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>December 31, 2019</b> &#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td style="vertical-align: top; padding-bottom: 1.5pt">&#160;</td> <td colspan="3" style="vertical-align: bottom"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>March 31, 2019</b> &#160; &#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: top"> <td style="width: 43%">&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 10%; text-align: center"><font style="font-size: 8pt">Principal</font></td> <td style="width: 8%; text-align: center"><font style="font-size: 8pt">Accrued</font></td> <td style="width: 8%">&#160;</td> <td style="width: 2%">&#160;</td> <td style="width: 10%; text-align: center"><font style="font-size: 8pt">Principal</font></td> <td style="width: 8%; text-align: center"><font style="font-size: 8pt">Accrued</font></td> <td style="width: 10%">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Balance</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Interest</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Total</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td>&#160;</td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Balance</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Interest</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center">Total</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td><font style="font-size: 8pt">7.75% and 7.15% Notes payable</font></td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr style="vertical-align: top"> <td><font style="font-size: 8pt">to insurance premium financing company (current)</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 70,500</font></td> <td style="text-align: right"><font style="font-size: 8pt">&#160;$ -</font></td> <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 70,500</font></td> <td>&#160;</td> <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 57,300</font></td> <td style="text-align: right"><font style="font-size: 8pt">&#160;$ -</font></td> <td style="text-align: right"><font style="font-size: 8pt">&#160;$ 57,300</font></td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, we executed a 7.15% promissory note in the principal amount of $230,200 in connection with certain insurance policy premiums. The note is payable in monthly installments of $23,800, including principal and interest, through March 2020, and had an outstanding principal balance of $70,500 at December 31, 2019. In February 2019, we executed a 7.75% promissory note in the principal amount of $63,500 in connection with other insurance policy premiums. That note was payable in monthly installments of $6,600 including principal and interest, through December 2019 and was fully paid at December 31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At our Annual Meeting of Stockholders on September 5, 2019, as approved by and recommended to our stockholders by our Board, our stockholders approved an amendment to our Restated Articles of Incorporation to increase the authorized number of shares of common stock that we may issue from 100.0 million shares to 175.0 million shares. The amendment became effective on September 6, 2019, upon our filing of a certificate of amendment with the Nevada Secretary of State.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fall 2019 Private Placement</i>&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Between October 30, 2019 and November 7, 2019, in a self-placed private placement and pursuant to subscription agreements received from certain accredited investors, we sold to such investors units, at a purchase price of $1.00 per unit, consisting of an aggregate of 650,000 unregistered shares of our common stock and warrants, exercisable beginning six months following issuance and through November 1, 2023, to purchase 325,000 unregistered shares of our common stock at an exercise price of $2.00 per share (the <i>Fall 2019 Private Placement</i>). We received cash proceeds of $650,000 from the Fall 2019 Private Placement.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As further described below under &#8220;Winter 2019 Warrant Modification,&#8221; in December 2019, we modified the warrants issued in connection with the Fall 2019 Private Placement to (i) reduce the exercise price from $2.00 per share to $0.50 per share and (ii) to allow for the warrants to become immediately exercisable. Further, we issued warrants to purchase an aggregate of 325,000 additional shares of our common stock to the participants in the Fall 2019 Private Placement (the <i>Additional Warrants</i>) to increase the number of unregistered shares of common stock issuable upon exercise of the warrants from 50% to 100%. The Additional Warrants are immediately exercisable through March 31, 2024 at an exercise price of $0.50 per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculated the fair value of the Additional Warrants using the Black Scholes Option Pricing Model and the weighted average assumptions indicated in the table below, recognizing $88,800 as the fair value of the new warrants and as warrant modification expense, included as a component of general and administrative expenses, in our Condensed Consolidated&#160;Statement of Operations and Comprehensive Loss for the three and nine months ended December 31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-weight: bold; text-align: justify; font-size: 8pt">Assumption:</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="font-size: 8pt"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Additional Warrants</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p></td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 87%; text-align: justify; font-size: 8pt">Market price per share</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; text-align: left; font-size: 8pt">$</td><td style="width: 10%; text-align: right; font-size: 8pt">0.44</td><td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">$</td><td style="text-align: right; font-size: 8pt">0.50</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1.59</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Contractual term in years</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">4.32</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">86.64</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">0.0</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Number of warrant shares</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">325,000</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-weight: bold; font-size: 8pt">Weighted average fair value per share</td><td style="font-weight: bold; font-size: 8pt">&#160;</td> <td style="font-weight: bold; text-align: left; font-size: 8pt">$</td><td style="font-weight: bold; text-align: right; font-size: 8pt">0.27</td><td style="font-weight: bold; text-align: left; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Winter 2019 Warrant Modification</i></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 4, 2019, we modified outstanding warrants previously issued as a part of completed private placements to temporarily reduce, for a period of two years or, if sooner, until the expiration of the warrant, the exercise price of such warrants to $0.50 per share, in order to more closely align the exercise price of the warrants with the trading price of our common stock at such time (the <i>Winter 2019 Warrant Modification</i>). Following the two-year period during which the exercise price is reduced, the exercise price of each modified warrant will revert to its pre-modification price. As a result of the Winter 2019 Warrant Modification, outstanding warrants to purchase a total of approximately 6.6 million unregistered shares of our common stock were modified.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculated the fair value of the modified warrants, including those issued in the Fall 2019 Private Placement, immediately before and after the modification using the Black Scholes Option Pricing Model for pre-modification valuations and for post-modification valuations for warrants expiring in less than two years. For the warrants expiring after the December 4, 2021 exercise price reversion date, we ran a binomial model using 24 steps, one for each month, and lognormal distribution to estimate our stock price at December 4, 2021, the termination date for the exercise price reduction. We then compared the exercise value of each warrant at each estimated stock price to the remaining option value if the warrant was not exercised on December 4, 2021 and allowed to revert to its original exercise price. For any estimated stock price above $0.50 per share (an in-the-money warrant), we determined that the holders would convert their warrants. For any estimated stock price below $0.50 per share, we determined that the holders would continue to hold their warrants. Given the significant reductions in exercise price (the pre-modification exercise prices range from $1.50 to $2.24 per share), if the warrants are not exercised prior to December 4, 2021, the Black-Scholes values upon the reversion of the exercise prices are very low, such that there is nominal additional value for continuing to hold the warrants. Accordingly, our estimated post-modification fair value for warrants having an expiration date later than the two-year exercise price reversion date, December 4, 2021, is equal to the value of an option determined using the Black Scholes Option Pricing Model having an exercise price of $0.50 per share and a two-year term and related assumptions. The table below indicates the pre- and post-modification weighted average assumptions used in our valuations. We recognized the incremental fair value, $702,500, as warrant modification expense, included as a component of general and administrative expenses, in our Condensed Consolidated&#160;Statement of Operations and Comprehensive Loss for the three and nine months ended December 31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-weight: bold; text-align: justify; font-size: 8pt">Assumption:</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="text-align: center; font-size: 8pt"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Pre-modification</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p></td><td style="text-align: center; font-size: 8pt">&#160;</td> <td colspan="3" style="text-align: center; font-size: 8pt"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Post-modification</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 74%; text-align: justify; font-size: 8pt">Market price per share</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; text-align: left; font-size: 8pt">$</td><td style="width: 10%; text-align: right; font-size: 8pt">0.44</td><td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; text-align: left; font-size: 8pt">$</td><td style="width: 10%; text-align: right; font-size: 8pt">0.44</td><td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">$</td><td style="text-align: right; font-size: 8pt">1.98</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">$</td><td style="text-align: right; font-size: 8pt">0.50</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1.58</td><td style="text-align: left; font-size: 8pt">%</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1.58</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Remaining contractual term in years</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">2.25</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1.91</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">87.5</td><td style="text-align: left; font-size: 8pt">%</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">88.1</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">0.0</td><td style="text-align: left; font-size: 8pt">%</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">0.0</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Number of warrant shares</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">6,611,759</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">6,611,759</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-weight: bold; text-align: justify; font-size: 8pt">Weighted average fair value per share</td><td style="font-weight: bold; font-size: 8pt">&#160;</td> <td style="font-weight: bold; text-align: left; font-size: 8pt">$</td><td style="font-weight: bold; text-align: right; font-size: 8pt">0.08</td><td style="font-weight: bold; text-align: left; font-size: 8pt">&#160;</td><td style="font-weight: bold; font-size: 8pt">&#160;</td> <td style="font-weight: bold; text-align: left; font-size: 8pt">$</td><td style="font-weight: bold; text-align: right; font-size: 8pt">0.19</td><td style="font-weight: bold; text-align: left; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Following the Winter 2019 Warrant Modification, investors holding a total 820,000 warrants elected to exercise their warrants at the reduced price of $0.50 per share, resulting in proceeds to us of $410,000.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>December 19, 2019 Warrant Modification</i></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On December 19, 2019, we modified outstanding warrants previously issued as a part of a completed private placement to permanently reduce the exercise price of such warrants to $0.805 per share and to extend the term of such warrants through December 31, 2022, in order to more closely align the exercise price of the warrants with the current trading price of our common stock and to provide additional time for the holders to exercise the warrants (the <i>December 19, 2019 Warrant Modification</i>). As a result of the December 19, 2019 Warrant Modification, outstanding warrants to purchase a total of 80,431 shares of common stock were modified.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We calculated the fair value of the modified warrants immediately before and after the modification using the Black Scholes Option Pricing Model and the weighted average assumptions indicated in the table below. We recognized the incremental fair value, $35,600, as warrant modification expense, included as a component of general and administrative expenses, in our Condensed Consolidated&#160;Statement of Operations and Comprehensive Loss for the three and nine months ended December 31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-weight: bold; text-align: justify; font-size: 8pt">Assumption:</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="font-size: 8pt"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Pre-modification</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p></td><td style="text-align: center; font-size: 8pt">&#160;</td> <td colspan="3" style="text-align: center; font-size: 8pt"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Post-modification</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 74%; text-align: justify; font-size: 8pt">Market price per share</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; text-align: left; font-size: 8pt">$</td><td style="width: 10%; text-align: right; font-size: 8pt">0.805</td><td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; text-align: left; font-size: 8pt">$</td><td style="width: 10%; text-align: right; font-size: 8pt">0.805</td><td style="width: 1%; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">$</td><td style="text-align: right; font-size: 8pt">7.00</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">$</td><td style="text-align: right; font-size: 8pt">0.805</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1.57</td><td style="text-align: left; font-size: 8pt">%</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">1.65</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Remaining contractual term in years</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">0.58</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">3.034</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">98.7</td><td style="text-align: left; font-size: 8pt">%</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">84.9</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">0.0</td><td style="text-align: left; font-size: 8pt">%</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">0.0</td><td style="text-align: left; font-size: 8pt">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="text-align: justify; font-size: 8pt">Number of warrant shares</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">80,431</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">80.431</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-weight: bold; text-align: justify; font-size: 8pt">Weighted average fair value per share</td><td style="font-weight: bold; font-size: 8pt">&#160;</td> <td style="font-weight: bold; text-align: left; font-size: 8pt">$</td><td style="font-weight: bold; text-align: right; font-size: 8pt">0.00</td><td style="font-weight: bold; text-align: left; font-size: 8pt">&#160;</td><td style="font-weight: bold; font-size: 8pt">&#160;</td> <td style="font-weight: bold; text-align: left; font-size: 8pt">$</td><td style="font-weight: bold; text-align: right; font-size: 8pt">.044</td><td style="font-weight: bold; text-align: left; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Winter 2019 Warrant Offering</i></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In December 2019, we commenced a self-placed private placement of warrants to purchase unregistered shares of our common stock at an offering price of $0.15 per warrant (the <i>Winter 2019 Warrant Offering</i>). Warrants offered and sold in the Winter 2019 Warrant Offering have an exercise price of $0.50 per share and term of three years from the issuance date. Over the course of the Winter 2019 Warrant Offering, we sold warrants to purchase a total of 2.0 million unregistered shares of common stock for cash proceeds to us of $300,000, which we accounted for with a corresponding credit to additional paid-in capital, an equity account.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Warrants Outstanding</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes warrants outstanding and exercisable as of December 31, 2019 subsequent to the issuances and modifications described above. The weighted average exercise price of outstanding and exercisable warrants at December 31, 2019 is $1.88 per share and $1.90 per share, respectively.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td colspan="3" style="text-align: center; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Warrants</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Exercise</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Outstanding at</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Exercisable at</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Price</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Expiration</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">per Share</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; border-bottom: Black 1pt solid">&#160;<b>Date</b></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td colspan="3" style="text-align: center; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="text-align: center; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td colspan="3" style="text-align: center; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 23%; font-size: 8pt; text-align: right">0.50</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 8pt; text-align: right">5/20/2020 to 3/31/2024</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 8pt; text-align: right">8,116,759</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 8pt; text-align: right">7,791,759</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.805</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">12/31/2022</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">80,431</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">80,431</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.50</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">12/13/2022</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">9,596,200</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">9,596,200</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.82</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">3/7/2023</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,388,931</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,388,931</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">3.51</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">12/31/2021</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">50,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">50,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">5.30</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5/16/2021</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2,705,883</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2,705,883</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">7.00</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1/11/2020 to 3/3/2023</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,092,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,092,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">10.00</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1/11/2020</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">20,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">20,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font-size: 8pt">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">23,050,204</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left; font-size: 8pt">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right; font-size: 8pt">22,725,204</td><td style="padding-bottom: 2.5pt; text-align: left; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Of the warrants outstanding at December 31, 2019, 2,705,883 shares of common stock underlying the warrants exercisable at $5.30 per share issued in our May 2016 public offering, 1,388,931 shares of common stock underlying the warrants exercisable at $1.82 per share issued in our September 2017 public offering and 9,596,200 shares of common stock underlying the warrants exercisable at $1.50 per share issued in our December 2017 public offering are registered for resale by the warrant holders. The common shares issuable upon exercise of our remaining outstanding warrants are unregistered. At December 31, 2019, none of our outstanding warrants are subject to down round anti-dilution protection features and all of the outstanding warrants are exercisable by the holders only by payment in cash of the stated exercise price per share.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Cato Holding Company (<i>CHC</i>), doing business as Cato BioVentures (<i>CBV</i>), is the parent of Cato Research Ltd. (<i>CRL</i>). CRL is a contract research, development and regulatory services organization (<i>CRO</i>) that we have engaged for a wide range of material aspects related to the nonclinical and clinical development, manufacturing and regulatory affairs associated with our efforts to develop and commercialize PH94B, PH10, AV-101. At December 31, 2019, CBV held approximately 2% of our outstanding common stock.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2017, we entered into a Master Services Agreement (<i>MSA</i>) with CRL, which replaced a substantially similar May 2007 master services agreement, pursuant to which CRL may assist us in the evaluation, development, commercialization and marketing of our potential product candidates, and provide regulatory and strategic consulting services as requested from time to time. Specific projects or services are and will be delineated in individual work orders negotiated from time-to-time under the MSA. Under the terms of work orders issued pursuant to the July 2017 MSA and our prior May 2007 master services agreement, we incurred expenses of $842,100 and $1,075,800 during the quarters ended December 31, 2019 and 2018, respectively, and $3,858,000 and $2,705,600 for the nine months ended December 31, 2019 and 2018, respectively. At December 31, 2019 and March 31, 2019, we had recorded accounts payable and accrued expenses related to CRL aggregating $898,500 and $657,800, respectively. We anticipate periodic expenses for CRO services from CRL related to nonclinical and clinical development of, and regulatory affairs related to PH94B, PH10, AV-101 and other potential product candidates will increase in future periods.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During our fiscal year ended March 31, 2019, we issued an aggregate of 2,556,361 shares of our unregistered common stock having an issue-date fair market value of $4,250,000 to Pherin Pharmaceuticals, Inc. (<i>Pherin</i>) to acquire exclusive worldwide licenses to develop and commercialize PH94B and PH10. We recorded the acquisition of the licenses as research and development expense during our fiscal year ended March 31, 2019. During the quarters ended December 31, 2019 and 2018, we recorded $30,000 in each quarter, and during the nine months ended December 31, 2019 and 2018, we recorded $90,000 and $40,000, respectively, representing monthly support payments to Pherin under the terms of the PH94B license agreement. We recorded no amounts payable to Pherin at December 31, 2019 or March 31, 2019. At December 31, 2019, Pherin held approximately 3% of our outstanding common stock.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended December 31, 2019, we engaged the consulting firm headed by one of the independent members of our Board to provide various market research studies and commercial modeling projects for certain of our CNS pipeline candidates and recorded research and development expense of $5,600 for the quarter ended December 31, 2019 and $108,400 for the nine months ended December 31, 2019 related to such studies. We incurred no such expenses for the three months ended December 31, 2018 and $11,700 for the nine months ended December 31, 2018. We recorded no amounts payable at December 31, 2019 or March 31, 2019 related to these studies.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b><i>Operating Leases</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We lease our headquarters office and laboratory space in South San Francisco, California under the terms of a lease that expires on July 31, 2022 and that provides an option to renew for an additional five years at then-current market rates. Consistent with the guidance in ASC 842, effective beginning April 1, 2019, we have recorded this lease in our Condensed Consolidated Balance Sheet as an operating lease. For the purpose of determining the right-of-use asset and associated lease liability, we determined that the renewal of this lease is reasonably probable.&#160;The lease of our South San Francisco facilities does not include any restrictions or covenants requiring special treatment under ASC 842.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the presentation of the operating lease in our Condensed Consolidated Balance Sheet at December 31, 2019:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>As&#160;of&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>December 31, 2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p></td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic">Assets</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">Right of use asset &#8211; operating lease</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,665,600</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td> <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic">Liabilities</td><td style="font-size: 12pt">&#160;</td> <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Current operating lease obligation</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">301,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Non-current operating lease obligation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,798,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Total operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,099,800</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the effect of operating lease costs in the Company&#8217;s condensed consolidated statements of operations:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center">&#160;</td><td style="text-align: center">&#160;</td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>For&#160;the&#160;Three&#160;Months&#160;Ended</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p></td><td style="font-weight: bold; text-align: center">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center">For&#160;the&#160;Nine&#160;Months&#160;Ended</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>December 31, 2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p></td><td style="text-align: center"><b>&#160;</b></td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>December 31, 2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p></td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; text-align: left">Operating lease cost</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">203,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">615,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The minimum (base rental) lease payments related to our South San Francisco operating lease are expected to be as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: left">Fiscal Years Ending March 31,</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 48%; text-align: left"><font style="font-size: 8pt">2020 (remaining three months)</font></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right">157,800</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">645,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">668,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">726,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">766,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Thereafter</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Total lease expense</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,684,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Less imputed interest</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,584,600</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Present value of operating lease liabilities</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,099,800</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Under the prior lease guidance, future minimum lease payments, under the non-cancellable portion (excluding the five-year extension assumed under ASC 842) of the South San Francisco operating lease were as follows at March 31, 2019:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: left">Fiscal Years Ending March 31,</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 48%; text-align: left">2020</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right">623,900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">645,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">668,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">225,300</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Thereafter</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,163,400</td><td style="text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">The remaining lease term, including the assumed five-year extension at the expiration of the current lease period, and the discount rate assumption for our South San Francisco operating lease is as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center"><b>As&#160;of&#160;December 31,&#160;2019</b></td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">Assumed remaining lease term in years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">7.58</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Assumed discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.54</td><td style="text-align: left">%</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The interest rate implicit in lease contracts is typically not readily determinable and, as such, we used our estimated incremental borrowing rate based on information available at the adoption of ASC 842, which represents an internally developed rate that would be incurred to borrow, on a collateralized basis, over a similar term, an amount equal to the lease payments in a similar economic environment.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Supplemental disclosure of cash flow information related to the Company&#8217;s operating leases included in cash flows used by operating activities in the condensed consolidated statements of cash flows is as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center"><b>For&#160;the&#160;Nine Months&#160;Ended</b></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>December 31, 2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p></td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">561,900</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-indent: 45pt">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the nine months ended December 31, 2019, other than the initial adoption of ASC 842 that required right of use assets and lease liabilities to be recorded, we recorded no new right of use assets arising from new lease liabilities.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We also lease a small office in the San Francisco Bay Area under a month-to-month arrangement at insignificant cost and have made an accounting policy election not to apply the ASC 842 operating lease recognition requirements to such short-term lease. We recognize the lease payments for this lease in general and administrative expense over the lease term.&#160;We recorded rent expense of $3,500 and $10,500 for the three and nine months ended December 31, 2019, respectively, attributable to this lease.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have evaluated subsequent events through February 13, 2020 and have identified the following matters requiring disclosure:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Registered Direct Offering of Common Stock and Concurrent Warrant Offering</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January&#160;24, 2020, we entered into a securities purchase agreement with certain accredited investors pursuant to which we received gross cash proceeds of $2.75 million upon the sale of an aggregate of 3,870,077 shares of our common stock at a purchase price of $0.71058 per share (the <i>January 2020 Offering</i>). Concurrently with the January 2020 Offering, we also commenced a private placement in which we issued and sold warrants (the <i>Warrants</i>) exercisable for an aggregate of 3,870,077&#160;unregistered shares of our common stock (the <i>Warrant Shares</i>), having an exercise price of $0.73 per Warrant Share. The 3,870,077 shares of common stock sold in the January 2020 Offering (but not the Warrants or the Warrant Shares) were offered and sold pursuant to a prospectus, dated September 30, 2019, and a prospectus supplement dated January&#160;24, 2020, in connection with a takedown from our shelf registration statement on&#160;Form&#160;S-3&#160;(File&#160;No.&#160;333-234025).</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">The Warrants contain customary provisions allowing for adjustment to the exercise price and number of Warrant Shares issuable only in the event of any stock dividend and split, reverse stock split, recapitalization, reorganization or similar transaction, as described in the Warrants.</font> In addition, <font style="background-color: white">subject to limited exceptions, holders of the Warrants will not have the right to exercise any portion of their respective Warrants if the holder, together with any affiliates, would beneficially own in excess of 4.99% of the number of shares of our Common Stock outstanding immediately after giving effect to such exercise.</font> The Warrants are exercisable from any time after the six-month anniversary of issuance (the <i>Initial Exercise Date</i>) and will expire on the fifth&#160;year anniversary of the Initial Exercise Date. The Warrants and the Warrants Shares have not been registered with the Securities and Exchange Commission.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Grant of Options from the 2019 Plan</i></b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2020, we issued options to purchase 75,000 shares of our common stock at an exercise price of $0.7074 per share pursuant to the 2019 Plan to a consultant as partial compensation under a professional services contract. The options were vested 25% upon grant with the remaining shares vested ratably over the next twelve months.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.&#160;&#160;Significant estimates include those relating to share-based compensation, right-of-use assets and lease liabilities and assumptions that have been used historically to value warrants and warrant modifications. With the exception of the BlueRock/Bayer Agreement pursuant to which we recorded sublicense revenue in the third quarter of our fiscal year ended March 31, 2017, we do not currently have, nor have we had during the periods covered by this Report, any arrangements requiring the recognition of revenue.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Research and development expenses are composed of both internal and external costs.&#160;&#160;Internal costs include salaries and employment-related expenses, including stock-based compensation expense, of scientific personnel and direct project costs.&#160;&#160;External research and development expenses consist primarily of costs associated with clinical and non-clinical development of PH94B, PH10, AV-101, and stem cell research and development costs, and costs related to the application and prosecution of patents related to those product candidates and, to a lesser extent, our stem cell technology platform. All such costs are charged to expense as incurred. We also record accruals for estimated ongoing clinical trial costs. Clinical trial costs represent costs incurred by contract research organizations (<i>CRO</i>s) and clinical trial sites. Progress payments are generally made to CROs, clinical sites, investigators and other professional service providers. We analyze the progress of the clinical trial, including levels of subject enrollment, invoices received and contracted costs when evaluating the adequacy of accrued liabilities. Significant judgments and estimates must be made and used in determining the clinical trial accrual in any reporting period. Actual results could differ from those estimates under different assumptions. Revisions are charged to research and development expense in the period in which the facts that give rise to the revision become known. Costs incurred in obtaining product or technology licenses are charged immediately to research and development expense if the product or technology licensed has not achieved regulatory approval or reached technical feasibility and has no alternative future uses. In September and October 2018, we acquired exclusive worldwide licenses to develop and commercialize PH94B and PH10, respectively, by issuing an aggregate of 2,556,361 unregistered shares of our common stock having an issuance-date fair market value of $4,250,000. Since, at the date of each acquisition, neither product candidate had achieved regulatory approval and each requires significant additional development and expense, we expensed the costs related to acquiring the licenses and the option during our fiscal year ended March 31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="margin: 0pt; font-size: 8pt"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We recognize compensation cost for all stock-based awards to employees and non-employee consultants based on the grant date fair value of the award.&#160;&#160;We record non-cash, stock-based compensation expense over the period during which the employee or other grantee is required to perform services in exchange for the award, which generally represents the scheduled vesting period.&#160;&#160;We have not granted restricted stock awards to employees nor do we have any awards with market or performance conditions.&#160;Non-cash expense attributable to compensatory grants of stock to non-employees is determined by the quoted market price of the stock on the date of grant and is either recognized as fully-earned at the time of the grant or amortized ratably over the term of the related service agreement, depending on the terms of the specific agreement.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below summarizes stock-based compensation expense included in the accompanying Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended December 31, 2019 and 2018.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;Three Months Ended December 31,</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;Nine Months Ended December 31,</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2019</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2018</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2019</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2018</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 50%; font-size: 8pt">&#160;Research and development expense</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">502,500</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">274,900</td> <td style="width: 2%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">1,060,600</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">955,600</td> <td style="width: 2%; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;General and administrative expense</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">1,129,700</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">459,800</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">2,028,100</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">1,564,100</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;Total stock-based compensation expense</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">1,632,200</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">734,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">3,088,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">2,519,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, the Compensation Committee of our Board of Directors (the <i>Board</i>) approved the grant of options from our 2016 Amended and Restated Stock Incentive Plan (the <i>2016 Plan</i>) to purchase an aggregate of 1,220,000 shares of our common stock at a then above-market exercise price of $1.00 per share to the independent members of our Board, our officers and employees and certain consultants. The options vested 25% upon grant with the remaining shares vesting ratably over three years for independent directors, officers and employees, and over two years for consultants. We valued the options granted in May 2019 using the Black-Scholes Option Pricing Model and the following weighted average assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Assumption:</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid">May 2019</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 87%; font-size: 8pt; text-align: justify">Market price per share at grant date</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.80</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.00</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2.12</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Expected term in years</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.53</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">85.90</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.0</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,220,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold">Fair Value per share</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td style="font-size: 8pt; font-weight: bold; text-align: left">$</td><td style="font-size: 8pt; font-weight: bold; text-align: right">0.54</td><td style="font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in May 2019, the Compensation Committee approved, subject to subsequent stockholder approval at our 2019 Annual Meeting of Stockholders (<i>Annual Meeting</i>) held in September 2019, the 2019 Omnibus Equity Incentive Plan (the <i>2019 Plan</i>) and designated 7.5 million shares of our authorized common stock to be reserved thereunder. Further, in May 2019, the Compensation Committee granted options pursuant to the 2019 Plan to one of our officers to purchase 170,000 shares of our common stock at a then above-market exercise price of $1.00 per share, which grant was contingent upon the approval of the 2019 Plan by our stockholders. Our stockholders approved the 2019 Plan at our Annual Meeting and ratified the contingent grant. The option vested 25% upon approval of the 2019 Plan and the remaining shares vest ratably over three years. We valued the option using the Black-Scholes Option Pricing Model and the following assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Assumption:</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid">September 2019</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 87%; font-size: 8pt; text-align: justify">Market price per share at grant date</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.84</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.00</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.45</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Expected term in years</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.58</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">86.04</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: justify">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.0</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">170,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; font-weight: bold">Fair Value per share</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td style="font-size: 8pt; font-weight: bold; text-align: left">$</td><td style="font-size: 8pt; font-weight: bold; text-align: right">0.56</td><td style="font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon approval of the 2019 Plan by our stockholders, no further option or other equity awards were permitted from our 2016 Plan and all remaining authorized shares of our common stock available for issuance under the 2016 Plan, 1,388,412 shares, became available for issuance under the 2019 Plan.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended December 31, 2019, we granted options from our 2019 Plan to the independent members of our Board, our officers and employees and certain consultants to purchase an aggregate of 1,990,000 shares of our common stock at exercise prices ranging from $0.50 to $1.41 per share. Options granted to Board members, officers, employees and most consultants were vested 25% at grant with the remaining options vesting ratably over the following 24 months. In the case of options granted to certain consultants, the options were vested 25% at grant but the remaining vesting period was less than 24 months to coincide with contractual terms. We valued the options using the Black-Scholes Option Pricing Model and the following assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td colspan="12" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>Options Granted on</b>&#160; &#160; &#160;&#160; &#160; &#160;&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right; font-size: 8pt">&#160;</td><td style="padding-bottom: 1pt; text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="padding-bottom: 1pt; font-size: 8pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>October 21, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;November 7, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;December 4, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;December 15, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 48%; font-size: 8pt">Exercise price</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1.41</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1.20</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.50</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.70</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Market price on date of grant</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.41</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.01</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.44</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.70</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.62</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.74</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.60</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.66</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Expected term (years)</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.39</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">87.52</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.02</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.28</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.44</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt; text-align: left">Expected dividend yield</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="text-align: left; font-size: 8pt">&#160;</td><td style="text-align: right; font-size: 8pt">&#160;</td><td style="text-align: left; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Fair value per share at grant date</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.99</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.67</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.30</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.49</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">Number of shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,575,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">65,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">250,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">100,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At December 31, 2019, there were stock options outstanding under our 2016 Plan and 2019 Plan to purchase 9,928,088 shares of our common stock at a weighted average exercise price of $1.37 per share. At that date, there were also 6,805,162 shares of our common stock available for future issuance under the 2019 Plan. See Note 11, <i>Subsequent Events</i>, for disclosure of additional option grants made in January 2020.</p> <p style="margin: 0pt; font-size: 8pt"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 1, 2019, we adopted Financial Accounting Standards Board (<i>FASB</i>) Accounting Standards Update (<i>ASU</i>) No.&#160;2016-02,&#160;<i>Leases</i>, which replaced the existing guidance in Accounting Standards Codification (<i>ASC</i>) 840, &#8220;Leases&#8221;, and its subsequent amendments including ASU No. 2018-11,&#160;<i>Leases (Topic 842):</i> Targeted&#160;Improvements (<i>ASC 842</i>) using the modified transition method.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We determine whether an arrangement is an operating or financing lease at contract inception. Operating lease assets represent our right to use an underlying asset for the lease term and operating lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease payments over the lease term. When determining the lease term, we include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. In determining the present value of the lease payments, we use the interest rate implicit in the lease when it is readily determinable and we use our estimated incremental borrowing rate based upon information available at the commencement date when the implicit rate is not readily determinable.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The lease payments used to determine our operating lease assets include lease incentives and stated rent increases and may include escalation or other clauses linked to rates of inflation or other factors when determinable and are recognized in our operating lease assets in our condensed consolidated balance sheets.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our operating leases are reflected in right of use asset &#8211; operating leases, other current liabilities and non-current operating lease liability in our condensed consolidated balance sheets. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Short-term leases, defined as leases that have a lease term of 12 months or less at the commencement date, are excluded from this treatment and are recognized on a straight-line basis over the term of the lease.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Our accounting for financing leases, previously referred to as &#8220;capital leases&#8221; under prior guidance, remained substantially unchanged with our adoption of ASC 842. Financing leases are included in property and equipment, net and as current and non-current financing lease liabilities in our condensed consolidated balance sheets. Refer to &#8220;Recent Accounting Pronouncements&#8221; below and Note 10, <i>Commitments and Contingencies,</i> for additional information regarding our adoption of ASC 842 and its impact on our condensed consolidated financial statements.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have no components of other comprehensive loss other than net loss, and accordingly our comprehensive loss is equivalent to our net loss for the periods presented.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss attributable to common stockholders per share of common stock excludes the effect of dilution and is computed by dividing net loss increased by the accrual of dividends on outstanding shares of our Series B 10% Convertible Preferred Stock (<i>Series B Preferred</i>), by the weighted-average number of shares of common stock outstanding for the period. Diluted net loss attributable to common stockholders per share of common stock reflects the potential dilution that could occur if securities or other contracts to issue shares of common stock were exercised or converted into shares of common stock. In calculating diluted net loss attributable to common stockholders per share, we have generally not increased the denominator to include the number of potentially dilutive common shares assumed to be outstanding during the period using the treasury stock method because the result is antidilutive.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As a result of our net loss for all periods presented, potentially dilutive securities were excluded from the computation of diluted net loss per share, as their effect would be antidilutive. Potentially dilutive securities excluded in determining diluted net loss attributable to common stockholders per common share are as follows:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="7" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; font-size: 8pt; text-align: left">Series A Preferred stock issued and outstanding (1)</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 8pt; text-align: right">750,000</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 10%; font-size: 8pt; text-align: right">750,000</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Series B Preferred stock issued and outstanding (2)</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,160,240</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,160,240</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Series C Preferred stock issued and outstanding (3)</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2,318,012</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2,318,012</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Outstanding options under the Company's Amended and Restated 2016 (formerly 2008) Stock Incentive Plan and 2019 Omnibus Equity Incentive Plan</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">9,928,088</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">6,410,338</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">Outstanding warrants to purchase common stock</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">23,050,204</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">21,499,955</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; padding-bottom: 2.5pt">Total</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">37,206,544</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">32,138,545</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%; font-size: 8pt"> <tr style="vertical-align: top; font-size: 8pt"> <td style="width: 100%; font: 8pt Times New Roman, Times, Serif">(1) Assumes exchange under the terms of the October 11, 2012 Note Exchange and Purchase Agreement, as amended.</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td style="font: 8pt Times New Roman, Times, Serif">(2) Assumes exchange under the terms of the Certificate of Designation of the Relative Rights and Preferences of the Series B 10% Convertible Preferred Stock, effective May 5, 2015; excludes common shares issuable in payment of dividends on Series B Preferred upon conversion.</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td style="font: 8pt Times New Roman, Times, Serif">(3) Assumes exchange under the terms of the Certificate of Designation of the Relative Rights and Preferences of the Series C Convertible Preferred Stock, effective January 25, 2016.</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We do not use derivative instruments for hedging of market risks or for trading or speculative purposes. We carried no assets or liabilities that are measured on a recurring basis at fair value at December 31, 2019 or March&#160;31, 2019.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Except as described below, there have been no recent accounting pronouncements or changes in accounting pronouncements during the nine months ended December 31, 2019, as compared to the recent accounting pronouncements described in our Form 10-K for our fiscal year ended March 31, 2019, that are of significance or potential significance to us.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In February 2016, the FASB issued ASU No.&#160;2016-02,&#160;<i>Leases</i>, which replaced the existing guidance in ASC 840, &#8220;Leases&#8221;, and in July 2018, the FASB issued ASU No. 2018-11,&#160;<i>Leases (Topic 842):</i> Targeted&#160;Improvements (together, <i>ASC 842</i>). The new leasing standards set out the principles for the recognition, measurement, presentation and disclosure of leases for both parties to a contract (i.e. lessees and lessors). The new standards require lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification. Leases with a term of 12 months or less will be accounted for similar to the prior guidance for operating leases. We adopted the standards on the required effective date of April 1, 2019 and did not restate lease expense or lease-related assets or liabilities reported in prior comparative periods.&#160;Presentation of our financing lease for office equipment in the consolidated balance sheet is generally consistent with capitalized lease presentation under the prior lease accounting guidance. Presentation of leases within the consolidated statements of operations and consolidated statements of cash flows is generally consistent with the prior lease accounting guidance. We elected the package of practical expedients permitted under the transition guidance and, accordingly, the adoption of ASC 842 did not change the prior classification of any of our leases.&#160;We elected not to record a right-of-use asset or a lease liability on the balance sheet for leases with a term of 12 months or less and will recognize the associated lease payments in the consolidated statements of operations over the lease term.&#160;On the April 1, 2019 adoption date, we recognized approximately $4.3 million as total lease liabilities and $3.9 million as total right-of-use assets in our Condensed Consolidated Balance Sheet and derecognized a deferred rent liability of approximately $0.4 million attributable to the operating lease of our primary office and laboratory facilities recorded in accordance with prior guidance.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;Three Months Ended December 31,</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="6" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;Nine Months Ended December 31,</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2019</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2018</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2019</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center; font-size: 8pt"><b>&#160;2018</b></td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td> <td colspan="2" style="text-align: center; font-size: 8pt">&#160;</td> <td style="font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="width: 50%; font-size: 8pt">&#160;Research and development expense</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">502,500</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">274,900</td> <td style="width: 2%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">1,060,600</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">$</td> <td style="width: 9%; text-align: right; font-size: 8pt">955,600</td> <td style="width: 2%; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;General and administrative expense</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">1,129,700</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">459,800</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">2,028,100</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt solid; text-align: right; font-size: 8pt">1,564,100</td> <td style="padding-bottom: 1.5pt; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: bottom; font-size: 8pt"> <td style="font-size: 8pt">&#160;Total stock-based compensation expense</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">1,632,200</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">734,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">3,088,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td> <td style="border-bottom: black 1pt double; font-size: 8pt">$</td> <td style="border-bottom: black 1pt double; text-align: right; font-size: 8pt">2,519,700</td> <td style="padding-bottom: 3pt; font-size: 8pt">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In May 2019, the Compensation Committee of our Board of Directors (the <i>Board</i>) approved the grant of options from our 2016 Amended and Restated Stock Incentive Plan (the <i>2016 Plan</i>) to purchase an aggregate of 1,220,000 shares of our common stock at a then above-market exercise price of $1.00 per share to the independent members of our Board, our officers and employees and certain consultants. The options vested 25% upon grant with the remaining shares vesting ratably over three years for independent directors, officers and employees, and over two years for consultants. We valued the options granted in May 2019 using the Black-Scholes Option Pricing Model and the following weighted average assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Assumption:</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid">May 2019</td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; font-size: 8pt; text-align: justify">Market price per share at grant date</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.80</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.00</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2.12</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Expected term in years</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.53</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">85.90</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.0</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,220,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold">Fair Value per share</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td style="font-size: 8pt; font-weight: bold; text-align: left">$</td><td style="font-size: 8pt; font-weight: bold; text-align: right">0.54</td><td style="font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Additionally, in May 2019, the Compensation Committee approved, subject to subsequent stockholder approval at our 2019 Annual Meeting of Stockholders (<i>Annual Meeting</i>) held in September 2019, the 2019 Omnibus Equity Incentive Plan (the <i>2019 Plan</i>) and designated 7.5 million shares of our authorized common stock to be reserved thereunder. Further, in May 2019, the Compensation Committee granted options pursuant to the 2019 Plan to one of our officers to purchase 170,000 shares of our common stock at a then above-market exercise price of $1.00 per share, which grant was contingent upon the approval of the 2019 Plan by our stockholders. Our stockholders approved the 2019 Plan at our Annual Meeting and ratified the contingent grant. The option vested 25% upon approval of the 2019 Plan and the remaining shares vest ratably over three years. We valued the option using the Black-Scholes Option Pricing Model and the following assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold; text-align: justify; padding-bottom: 1pt">Assumption:</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid">September 2019</td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; font-size: 8pt; text-align: justify">Market price per share at grant date</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.84</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Exercise price per share</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.00</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.45</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Expected term in years</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.58</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">86.04</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: justify">Dividend rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.0</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">170,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; font-weight: bold">Fair Value per share</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td style="font-size: 8pt; font-weight: bold; text-align: left">$</td><td style="font-size: 8pt; font-weight: bold; text-align: right">0.56</td><td style="font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Upon approval of the 2019 Plan by our stockholders, no further option or other equity awards were permitted from our 2016 Plan and all remaining authorized shares of our common stock available for issuance under the 2016 Plan, 1,388,412 shares, became available for issuance under the 2019 Plan.</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the quarter ended December 31, 2019, we granted options from our 2019 Plan to the independent members of our Board, our officers and employees and certain consultants to purchase an aggregate of 1,990,000 shares of our common stock at exercise prices ranging from $0.50 to $1.41 per share. Options granted to Board members, officers, employees and most consultants were vested 25% at grant with the remaining options vesting ratably over the following 24 months. In the case of options granted to certain consultants, the options were vested 25% at grant but the remaining vesting period was less than 24 months to coincide with contractual terms. We valued the options using the Black-Scholes Option Pricing Model and the following assumptions:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td colspan="12" style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>Options Granted on</b>&#160; &#160; &#160;&#160; &#160; &#160;&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>October 21, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;November 7, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;December 4, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; font-weight: bold; text-align: right"><b>&#160;December 15, 2019</b></td><td style="padding-bottom: 1pt; font-size: 8pt; font-weight: bold; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">(weighted average)</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 48%; font-size: 8pt">Exercise price</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1.41</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1.20</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.50</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">0.70</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Market price on date of grant</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.41</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.01</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.44</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.70</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Risk-free interest rate</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.62</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.74</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.60</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1.66</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Expected term (years)</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.39</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5.06</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Volatility</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">87.52</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.02</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.28</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">88.44</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">Expected dividend yield</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">0.00</td><td style="font-size: 8pt; text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Fair value per share at grant date</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.99</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.67</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.30</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.49</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">Number of shares</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,575,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">65,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">250,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">100,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="7" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As of December 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2018</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; text-align: left">Series A Preferred stock issued and outstanding (1)</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">750,000</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">750,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Series B Preferred stock issued and outstanding (2)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,160,240</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1,160,240</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Series C Preferred stock issued and outstanding (3)</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,012</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,318,012</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Outstanding options under the Company's Amended and Restated 2016 (formerly 2008) Stock Incentive Plan and 2019 Omnibus Equity Incentive Plan</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">9,928,088</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,410,338</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left; padding-bottom: 1pt">Outstanding warrants to purchase common stock</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">23,050,204</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">21,499,955</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">37,206,544</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">32,138,545</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <table cellspacing="0" cellpadding="0" style="font: 8pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top; font-size: 8pt"> <td style="width: 70%; font-size: 8pt">____________</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 14%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 14%; font-size: 8pt">&#160;</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td colspan="5" style="font-size: 8pt">(1) Assumes exchange under the terms of the October 11, 2012 Note Exchange and Purchase Agreement, as amended.</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td colspan="5" style="font-size: 8pt">(2) Assumes exchange under the terms of the Certificate of Designation of the Relative Rights and Preferences of the Series B 10% Convertible Preferred Stock, effective May 5, 2015; excludes common shares issuable in payment of dividends on Series B Preferred upon conversion.</td></tr> <tr style="vertical-align: top; font-size: 8pt"> <td colspan="5" style="font-size: 8pt">(3) Assumes exchange under the terms of the Certificate of Designation of the Relative Rights and Preferences of the Series C Convertible Preferred Stock, effective January 25, 2016.</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="margin: 0pt; font-size: 8pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; font-size: 8pt; text-align: left">&#160;Clinical and nonclinical materials and contract services</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">121,000</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">5,900</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Fair value of securities issued for professional services</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8212;&#160;&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">105,900</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt">&#160;Insurance</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">119,300</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">96,300</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Public offering filing fees and expenses</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">30,500</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">22,300</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">&#160;Conferences, sponsorships and all other</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">48,200</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">20,500</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">319,000</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">250,900</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="width: 78%">&#160;</td> <td style="width: 11%"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;December 31,</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td style="width: 11%"> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;March 31,</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"><b>&#160;2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td> <td> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">&#160;&#160;&#160;&#160;&#160;&#160;clinical trial, development and related expenses</font></td> <td><font style="font-size: 8pt">&#160;$876,600&#160;</font></td> <td><font style="font-size: 8pt">&#160;$1,067,600&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">&#160;Accrued compensation</font></td> <td><font style="font-size: 8pt">&#160;&#160;-&#160;</font></td> <td><font style="font-size: 8pt">&#160;&#160;439,200&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 8pt">&#160;Accrued professional services</font></td> <td><font style="font-size: 8pt">&#160;&#160;66,800&#160;</font></td> <td><font style="font-size: 8pt">&#160;&#160;172,100&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 8pt">&#160;All other</font></td> <td><font style="font-size: 8pt">&#160;&#160;7,900&#160;</font></td> <td><font style="font-size: 8pt">&#160;&#160;6,700&#160;</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>&#160;</td> <td><font style="font-size: 8pt">&#160;$951,300&#160;</font></td> <td><font style="font-size: 8pt">&#160;$1,685,600&#160;</font></td></tr> </table> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Fall 2019 Private Placement</i></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Assumption:</td><td>&#160;</td> <td colspan="3"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Additional Warrants</b></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: justify">Market price per share</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.44</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Exercise price per share</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.59</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Contractual term in years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">4.32</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">86.64</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td> <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Number of warrant shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">325,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold">Weighted average fair value per share</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">0.27</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Winter 2019 Warrant Modification</i></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Assumption:</td><td>&#160;</td> <td colspan="3"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Pre-modification</b></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p></td><td style="text-align: center">&#160;</td> <td colspan="3" style="text-align: center"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p><p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Post-modification</b></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p></td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; text-align: justify">Market price per share</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.44</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.44</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Exercise price per share</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">1.98</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.50</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.58</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.58</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Remaining contractual term in years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2.25</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.91</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">87.5</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">88.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td> <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td> <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Number of warrant shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,611,759</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">6,611,759</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Weighted average fair value per share</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">0.08</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">0.19</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>December 19, 2019 Warrant Modification</i></p> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Assumption:</td><td>&#160;</td> <td colspan="3"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Pre-modification</b>&#160;</p></td><td style="text-align: center">&#160;</td> <td colspan="3" style="text-align: center"><p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&#160;</p><p style="font: 8pt/normal Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>Post-modification</b>&#160;</p></td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; text-align: justify">Market price per share</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.805</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">0.805</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Exercise price per share</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">7.00</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">0.805</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Risk-free interest rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.57</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">1.65</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Remaining contractual term in years</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.58</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3.034</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Volatility</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">98.7</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">84.9</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Dividend rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 11pt">&#160;</td><td style="font-size: 11pt">&#160;</td> <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt">&#160;</td> <td style="font-size: 11pt; text-align: left">&#160;</td><td style="font-size: 11pt; text-align: right">&#160;</td><td style="font-size: 11pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify">Number of warrant shares</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">80,431</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">80.431</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: justify">Weighted average fair value per share</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">0.00</td><td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold">&#160;</td> <td style="font-weight: bold; text-align: left">$</td><td style="font-weight: bold; text-align: right">.044</td><td style="font-weight: bold; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt/normal Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&#160;</p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Warrants</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Warrants</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Exercise</td><td>&#160;</td> <td colspan="3">&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Outstanding at</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Exercisable at</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Price</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">Expiration</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">per Share</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; border-bottom: Black 1pt solid; text-align: center">&#160;<b>Date</b></td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; text-align: center; border-bottom: Black 1pt solid"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>2019</b>&#160;</p></td></tr> <tr style="vertical-align: bottom"> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 23%; font-size: 8pt; text-align: right">0.50</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 8pt; text-align: right">5/20/2020 to 3/31/2024</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 8pt; text-align: right">8,116,759</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 22%; font-size: 8pt; text-align: right">7,791,759</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">0.805</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">12/31/2022</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">80,431</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">80,431</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.50</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">12/13/2022</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">9,596,200</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">9,596,200</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">1.82</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">3/7/2023</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,388,931</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,388,931</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">3.51</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">12/31/2021</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">50,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">50,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">5.30</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">5/16/2021</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2,705,883</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">2,705,883</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">7.00</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1/11/2020 to 3/3/2023</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,092,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1,092,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">$</td><td style="font-size: 8pt; text-align: right">10.00</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">1/11/2020</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">20,000</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">20,000</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td><td style="padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; text-align: right">&#160;</td><td style="padding-bottom: 1pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">23,050,204</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">22,725,204</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <p style="margin: 0pt"></p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>&#160;As&#160;of&#160;</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>December 31, 2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p></td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic">Assets</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">Right of use asset &#8211; operating lease</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">3,665,600</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td style="font-size: 12pt">&#160;</td> <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-style: italic">Liabilities</td><td style="font-size: 12pt">&#160;</td> <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: right">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Current operating lease obligation</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">301,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Non-current operating lease obligation</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">3,798,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Total operating lease liability</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,099,800</td><td style="text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>&#160;</b></p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>For&#160;the&#160;Three&#160;Months&#160;Ended</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p></td><td style="text-align: center"><b>&#160;</b></td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>&#160;</b></p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>For&#160;the&#160;Nine&#160;Months&#160;Ended</b></p></td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: center"><b>&#160;</b></td><td style="text-align: center"><b>&#160;</b></td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>December 31, 2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></p></td><td style="text-align: center"><b>&#160;</b></td> <td colspan="3" style="text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>December 31, 2019</b></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p></td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; text-align: left">Operating lease cost</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">203,100</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">615,000</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: left">Fiscal Years Ending March 31,</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 48%; text-align: left"><font style="font-size: 8pt">2020 (remaining three months)</font></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right">157,800</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">645,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">668,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">726,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">766,000</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Thereafter</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">2,720,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Total lease expense</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">5,684,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Less imputed interest</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">(1,584,600</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Present value of operating lease liabilities</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">4,099,800</td><td style="text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td colspan="3" style="font-weight: bold; text-align: left">Fiscal Years Ending March 31,</td><td>&#160;</td> <td colspan="3">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 48%; text-align: left">2020</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 47%; text-align: right">623,900</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2021</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">645,800</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2022</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">668,400</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2023</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">225,300</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left">2024</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">&#160;</td><td style="text-align: left"><font style="font-size: 8pt">Thereafter</font></td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;&#160;&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td style="font-size: 12pt; text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">$</td><td style="text-align: right">2,163,400</td><td style="text-align: left">&#160;</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3"><p style="font: 8pt Times New Roman, Times, Serif; margin: 0">&#160;</p><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><b>As&#160;of&#160;December 31,&#160;2019</b></p></td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">Assumed remaining lease term in years</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">7.58</td><td style="width: 1%; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left">Assumed discount rate</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">8.54</td><td style="text-align: left">%</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">For&#160;the&#160;Nine Months&#160;Ended</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 12pt">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">December 31, 2019</td></tr> <tr style="vertical-align: bottom"> <td style="width: 87%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%">&#160;</td> <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right">561,900</td><td style="width: 1%; text-align: left">&#160;</td></tr> </table> .80 .84 1.41 1.01 .44 .70 .44 .44 .44 .805 .805 0.50 0.805 1.50 1.82 3.51 5.30 7.00 10.00 1.00 1.00 1.41 1.20 .50 .70 .50 1.85 .50 7.00 .805 .0212 .0145 .0162 .0174 .0160 .0166 .0159 .0158 0.0158 .0157 .0165 P5Y6M11D P5Y6M29D P5Y4M20D P5Y22D P5Y22D P5Y22D P4Y3M25D P2Y3M P1Y10M28D P6M29D P3Y11D .8590 .8604 .8752 .8802 .8828 .8844 .8664 .8750 .8810 .9870 .8490 .0000 .0000 .0000 .0000 .0000 .0000 .0000 .0000 .0000 .0000 0.0000 .54 .56 .99 .67 .30 .49 .27 .08 .19 .00 .044 37206544 32138545 750000 750000 1160240 1160240 9928088 6410338 23050204 21499955 2318012 2318012 5900 121000 4099800 615000 203100 1584600 5684400 2720400 766000 726000 645800 157800 623900 645800 668400 225300 0 0 2163400 P7Y6M29D .0854 561900 5/20/2020 to 3/31/2024 12/31/2022 12/13/2022 3/7/2023 12/31/2021 5/16/2021 1/11/2020 to 3/3/2023 1/11/2020 23050204 8116759 80431 9596200 1388931 50000 2705883 1092000 20000 22725204 7791759 80431 9596200 1388931 50000 2705883 1092000 20000 <p style="font: 8pt Times New Roman, Times, Serif; margin: 0">Accrued expenses are composed of the following at December 31, 2019 and March 31, 2019:</p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Accrued expenses for AV-101, PH94B, and PH10</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; font-size: 8pt; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;clinical trial, development and related expenses</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">876,600</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1,067,600</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Accrued compensation</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8212;&#160;&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">439,200</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Accrued professional services</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">66,800</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">172,100</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">&#160;All other</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">7,900</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">6,700</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">951,300</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">1,685,600</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">December 31,</td><td style="font-size: 8pt; font-weight: bold">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center">March 31,</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td><td style="font-size: 8pt; font-weight: bold; padding-bottom: 1pt">&#160;</td> <td colspan="3" style="font-size: 8pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">2019</td></tr> <tr style="vertical-align: bottom"> <td>&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td><td>&#160;</td> <td colspan="3" style="text-align: center">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Accrued expenses for AV-101, PH94B, and PH10</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td> <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="width: 74%; font-size: 8pt; text-align: left">&#160;&#160;&#160;&#160;&#160;&#160;clinical trial, development and related expenses</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">876,600</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td><td style="width: 1%; font-size: 8pt">&#160;</td> <td style="width: 1%; font-size: 8pt; text-align: left">$</td><td style="width: 10%; font-size: 8pt; text-align: right">1,067,600</td><td style="width: 1%; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Accrued compensation</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">&#8212;&#160;&#160;</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">439,200</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left">&#160;Accrued professional services</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">66,800</td><td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt">&#160;</td> <td style="font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; text-align: right">172,100</td><td style="font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 8pt; text-align: left; padding-bottom: 1pt">&#160;All other</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">7,900</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 1pt">&#160;</td> <td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font-size: 8pt; text-align: right">6,700</td><td style="padding-bottom: 1pt; font-size: 8pt; text-align: left">&#160;</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 2.5pt">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">951,300</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td><td style="font-size: 8pt; padding-bottom: 2.5pt">&#160;</td> <td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 8pt; text-align: right">1,685,600</td><td style="padding-bottom: 2.5pt; font-size: 8pt; text-align: left">&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0"></p> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td colspan="10" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center"><b>December 31, 2019</b> &#160;</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td colspan="10" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center"><b>March 31, 2019</b> &#160; &#160;</td> <td style="vertical-align: bottom; padding-bottom: 1.5pt; font: 12pt Times New Roman, Times, Serif">&#160;</td></tr> <tr> <td style="vertical-align: top; width: 39%; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; width: 1%; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; width: 10%; font: 12pt Times New Roman, Times, Serif; text-align: center">Principal</td> <td style="vertical-align: top; width: 9%; font: 12pt Times New Roman, Times, Serif; text-align: center">Accrued</td> <td style="vertical-align: top; width: 9%; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; width: 3%; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; width: 10%; font: 12pt Times New Roman, Times, Serif; text-align: center">Principal</td> <td style="vertical-align: top; width: 9%; font: 12pt Times New Roman, Times, Serif; text-align: center">Accrued</td> <td style="vertical-align: top; width: 10%; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="width: 0%">&#160;</td> <td style="width: 0%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="width: 0%">&#160;</td> <td style="width: 3%">&#160;</td> <td style="width: 1%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="width: 1%">&#160;</td> <td style="width: 0%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="width: 0%">&#160;</td> <td style="width: 1%">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td style="width: 1%">&#160;</td></tr> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">Balance</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">Interest</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">Total</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">Balance</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">Interest</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td> <td colspan="2" style="vertical-align: bottom; border-bottom: black 1pt solid; font: 12pt Times New Roman, Times, Serif; text-align: center">Total</td> <td style="vertical-align: bottom; font: 12pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&#160;</td></tr> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">7.75% and 7.15% Notes payable</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> <tr> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">to insurance premium financing company (current)</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: right">&#160;$ 70,500</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: right">&#160;$ -</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: right">&#160;$ 70,500</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif">&#160;</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: right">&#160;$ 57,300</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: right">&#160;$ -</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: right">&#160;$ 57,300</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td> <td>&#160;</td></tr> </table> <p style="font: 8pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p> Yes NV 001-37761 Common Stock, par value $0.001 per share VTGN NASDAQ